Molecular Mechanisms Governing Muscle Wasting in Cancer by Dasgupta, Aneesha
University of Nebraska Medical Center 
DigitalCommons@UNMC 
Theses & Dissertations Graduate Studies 
Spring 5-4-2019 
Molecular Mechanisms Governing Muscle Wasting in Cancer 
Aneesha Dasgupta 
University of Nebraska Medical Center 
Follow this and additional works at: https://digitalcommons.unmc.edu/etd 
 Part of the Cancer Biology Commons 
Recommended Citation 
Dasgupta, Aneesha, "Molecular Mechanisms Governing Muscle Wasting in Cancer" (2019). Theses & 
Dissertations. 366. 
https://digitalcommons.unmc.edu/etd/366 
This Dissertation is brought to you for free and open access by the Graduate Studies at DigitalCommons@UNMC. It 
has been accepted for inclusion in Theses & Dissertations by an authorized administrator of 
DigitalCommons@UNMC. For more information, please contact digitalcommons@unmc.edu. 
 
 






Presented to the Faculty of Nebraska Graduate College  
in Partial Fulfillment for the Requirements of  
the Degree of Doctor of Philosophy 
 
 
Biochemistry and Molecular Biology Graduate Program 
Under the Supervision of Dr. Pankaj K. Singh 
April 2019 
 
Supervisory Committee Members 
 
 
Dr. Angie Rizzino, Ph.D.                                                             Dr. Keith Johnson, Ph.D. 











Dedicated to my parents and brother who never laughed at my dreams. 









I am grateful to my Ph.D. mentor, Dr. Pankaj K. Singh. He has been responsible 
in inspiring, motivating and guiding me through my entire PhD journey. He has 
made me the best version of the graduate student that I could be. All the accolades 
and the awards that I have received in these last four years is due to his investment 
in me. He was able to instill the same amount of ambition, drive and motivation in 
me, which he has, for science and for making a difference. He has always asked 
me to look at grander scheme of events. We have not always agreed with each 
other, but he has always supported me when I needed him to.  I have learnt a lot 
from him and I would like to thank him for contributing his time and effort in building 
my scientific acumen. 
I would also like to thank all the past and current lab members. Each of them 
has contributed to my scientific journey. I would like to start by thanking Dr. 
Surendra K. Shukla. He has guided and taught me most of my skills that I attained 
in the study of cancer cachexia. He has always been available to answer all my 
questions and confusions and to oversee my experiments. I would like to thank Dr. 
Enza Vernucci, for being a constant inspiration to me in the lab and to teach me to 
keep working hard through all the frustrations and the failures. My time in the PhD 
program would not have been half as enjoyable and fulfilling without her beside 
me. I would also like to thank Dr. Jaime Abrego, Ryan King and Scott Mulder, who 
are not just my fellow graduate students, but have eventually become few of my 
best friends. These are the people with whom I have spent each day for the last 5 
years. They have always helped me in dealing with large groups of mice surgeries, 
iii 
 
late night mice necropsies and any other help that I have ever needed. They have 
been there through all the ups and downs in my PhD; we have celebrated the 
sorrows and the joys of all our experiments together. I would also like to thank Dr. 
Ravi Thakur with whom I have always had the most enlightening scientific 
arguments. He has never hesitated to help me or to answer my questions. This 
section is incomplete without mentioning Nina Chaika. I would like to thank her for 
being patient with me since the first year and to help me whenever I needed her. 
Somehow, she always had answers to all my technical struggles. My lab members 
would agree when I say that the lab would not be held together without her constant 
efforts. 
I am immensely grateful to my entire supervisory committee, Dr. Keith 
Johnson, Dr. Angie Rizzino, Dr. Pi- Wan Cheng and Dr. Melissa Teoh-Fitzgerald. 
They have been guiding me in my attempt to answer the scientific questions that I 
was pursuing in my dissertation studies. Their inputs and feedback have made my 
research stronger and richer. I have enjoyed the constructive criticism of my work 
and I want to thank them for their contribution in making me a better scientist. I 
would also like to thank Dr. Rebecca Deegan and Dr. Matthew Zimmerman for 
helping me navigate through the ROS studies with deeper understanding. My 
studies also wouldn’t have been complete without the help of our clinical 
collaborators - Dr. Lyudmyla Berim, Dr. Mridula Krishnan and Dr. Lei Yu- all of 
whom have contributed to my clinical insight into pancreatic cancer cachexia. 
I would like to thank all my friends in Omaha, who became my second family 
Especially, Shrey, Tanmay and Deep – without whom I wouldn’t have been the 
iv 
 
best version of myself. I would also like to thank - Aishwarya, Rajvi, Pravin, 
Navneet, Keenan, Tayla and Nicole. Without them, these five years wouldn’t have 
been as enjoyable as it has been. My closest friends back home in Delhi, India- 
Sudipta, Pearl, Yachna, Eshan, Raghav and Avinash- have been my constant 
pillars of support and have cheered me on all these years, irrespective of the 
distance. All these people make me the person who I am today. 
Lastly, I would like to express my never-ending gratitude to my entire family. 
I always like to say that my parents gave me wings to fly but roots to stay grounded. 
They have empowered me in every possible way and never told me something is 
impossible for me to achieve. My brother, Arjun has been a constant strength for 
me and has taught me to face everything with a smile and a calm mind. My 
grandparents have always encouraged me to pursue my dreams in the face of 
societal pressures, for which I am always grateful. I would like to end by thanking 
my cousin Shonali, brother-in-law Joe, Uncle Scott, Aunt Santwana and Uncle 
Jayanta who have been there for me in the States, when I have been far away 
from home. 
It took all these people and more for me to be able to finish this journey amid 
frustrations and anxiety. 






Molecular Mechanisms Governing Muscle Wasting in Cancer 
Aneesha Dasgupta, Ph.D. 
University of Nebraska Medical Center, 2019 
 
Supervisor: Pankaj K. Singh, Ph.D. 
Pancreatic cancer is the third-leading cause of cancer-related deaths in the United 
States. About 80 percent of the pancreatic cancer patients suffer from cachexia 
and, about one-third die due to complexities related to the syndrome. Cachexia 
leads to a loss in body weight and cachectic patients are refractory to 
chemotherapy. Despite recent advances, the mechanisms of pancreatic cancer- 
cachexia and the potential therapeutic interventions remain poorly evaluated.  
Sirtuins represent a class of proteins that are regulated by metabolic 
fluctuations in tissues. We observed a reduced expression of Sirt1 in spontaneous 
PDAC mice muscles, human pancreatic cancer muscles, and myotubes treated by 
cancer cell-conditioned media. We further observed that cancer cell-conditioned 
media upregulated the NF-κB and FoxO transcription factor pathways. NF-κB 
regulated the expression of NADPH Oxidase (Nox4) in cachectic muscles, thereby 
increasing reactive oxygen species (ROS). We also observed a negative 
correlation between Nox4 expression and muscle cross-sectional area in the 
cachectic muscles of PDAC patients. Inducible genetic knockout of Nox4 gene in 
muscles of tumor-bearing mice rescued the cachectic phenotype. Moreover, 
pharmacological blockade of Nox4 activity was successful in attenuating loss in 
body weight and muscle mass in tumor-bearing mice. Therefore, we concluded 
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that the Sirt1-Nox4 axis plays an important role in the manifestation of pancreatic 
cancer cachexia. 
Studies have shown that chemotherapy in addition to tumor burden can 
induce body weight loss in cancer patients. We performed a single-center 
retrospective study of 162 patients at our institution by measuring muscle mass 
among patients with a diagnosis of pancreatic cancer at initial diagnosis and eight-
week follow up post treatment. We found a significant improvement in overall 
survival and progression-free survival in patients with modest or no reduction in 
skeletal muscle index after eight weeks of chemotherapy. Furthermore, we treated 
mice with Gemcitabine and FOLFIRINOX, and observed a decrease in body 
weight, gastrocnemius muscle weight, grip-strength, and rotarod performance. We 
also observed an increase in chemotherapy-induced ROS in the mice. We 
observed that utilizing BMX-001, a SOD mimetic rescued the decrease in body 
weight, muscle weight, grip-strength, and rotarod performance in mice treated with 
chemotherapy. BMX-001 was also successful in rescuing chemotherapy-induced 
muscle wasting in tumor-bearing mice. We concluded that targeting ROS 
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Chapter 1: Introduction 
(Note – The introduction is adapted from a review article which is under revision 
for submission as of April 2019) 
 
The word cachexia is derived from the Greek words, “Kakos” meaning bad and 
“Hexis” meaning condition. It is a multifactorial syndrome leading to loss in body 
weight and is associated with many diseases, majorly cancer, AIDS, tuberculosis, 
and chronic obstructive pulmonary disorder. The diagnostic criteria for cachexia is 
defined as 5% loss in body weight over a duration of six months or 2% loss in body 
weight for those whose body mass index (BMI) is less than 20 kg/m2. However, 
this diagnostic criterion did not include the prognostic significance of weight loss in 
patients who initially have a low, intermediate, and high BMI. In 2015, the 
diagnostic criteria for cachexia was revised by the consensus group and is now 
included in the international practice guidelines of the European Society for Clinical 
Nutrition and Metabolism (ESPEN)1. The group demonstrated differences in 
survival across five categories of BMI (< 20.0, 20.0 to 21.9, 22.0 to 24.9, 25.0 to 
27.9, and 28.0 kg/m2) and five categories of percent weight loss (WL) (-2.5 to -5.9, 
-6.0 to -10.9, -11.0 to -14.9, ≥ 15.0%, and weight stable (±2.4%). They observed 
that weight-stable patients with BMI ≥ 25.0 kg/m2 (grade 0) had the longest survival 
and percentage WL values associated with lower categories of BMI were related 
to shorter survival1. 
Cachexia differs from starvation in the way that the weight loss is due to 
depletion in adipose tissues and skeletal muscle mass but not non-muscle 
protein2. Moreover, cachexia also differs from anorexia in the way that the loss in 
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muscle and adipose deposits cannot be reversed by conventional nutritional 
support and thus leads to progressive functional impairment3. 
Previous studies have shown that cachexia is responsible for about 20% of 
deaths of cancer patients4, although this percentage varies with the tumor type, 
with an incidence of about 80%  in pancreatic cancer patients, 40 to 50%  in lung, 
prostate and colon cancer patients5,6 
The severity of cancer cachexia is inversely related to the survival of the 
patient and it almost always leads to a poor prognosis. The main characteristics of 
cancer cachexia is asthenia or lack of muscular strength. This entails the muscle 
wastage as well as physical and mental fatigue. Along with it, loss in mean body 
mass is the other trend in cachexia. It has also been observed that along with loss 
in skeletal muscle, loss in cardiac muscle also occurs in cancer cachectic patients. 
This might be a major reason of death in cachectic patients. The onset of cachexia 
significantly influences the course of the disease. Furthermore, most anti-tumor 
therapies also lead to muscle wasting and exacerbate the condition7. Body weight 
loss negatively influences survival by prevention of completion of chemotherapy. 
Cachexia affects the metabolism of the entire host body as it affects multiple 
organs. The severity of cachexia has been difficult to assess objectively and only 
recently a method to stage cachexia has been validated8.  
1. Diagnostic Techniques 
 
Cachexia is typically diagnosed if a patient has lost 5% of their body weight over a 
duration of 6 months or 2% of their body weight for those with a BMI of less than 
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20 kg/m2. Moreover, though none of them are in clinical use yet, there are several 
potential biomarkers which may be used to identify patients even before they show 
signs of cachexia or weight loss. Plasma levels of ghrelin, leptin and adiponectin 
have been found to be significantly higher in cachectic gastric cancer patients as 
compared to non-cachectic gastric cancer patients9. Moreover, the plasma levels 
of c-reactive protein (CRP) has been shown to be increased in the plasma of 
cachectic cancer patients10.  
A computed topography (CT) scan at the lumbar vertebrae level 3-4 is also 
being utilized to measure skeletal muscle mass, which can detect small changes 
and can be used to diagnose cachexia. Skeletal muscle can be identified around 
the L3 and then demarcated and quantified based on preestablished Hounsfield 
units (HU). Patients can be compared directly based on the  measurements around 
the lumbar region which can be correlated to whole body skeletal muscle11,12. 
Magnetic resonance imaging, appendicular skeletal muscle index from dual 
energy x-ray imaging (DEXA) , mid-upper arm muscle area by anthrophometry and 
whole body fat-free mass index by bioimpedence analysis are other methods to 
assess cachexia in cancer patients3,13,14. 
2. Cachexia Targets 
 
Cancer associated cachexia in patients affects more than just the skeletal 
muscles and the adipose tissues. It manifests effects on the whole body and 




a. Skeletal Muscle 
In almost all cancers, muscle and weight loss is correlated with poor prognosis, 
increased risk of treatment-related toxicity, and poor quality of life15,16. Additionally, 
preventing muscle wasting can directly improve survival in tumor-bearing mice17. 
Skeletal muscles comprise about 40% of the body weight and represent major 
protein reservoir of the body. Skeletal muscles not only provide strength and 
movement for the body, but also aid in maintaining posture and regulating body 
temperature. The major cause of weakness and fatigue in cachectic patients is 
muscle wasting18. The molecular basis of cancer-related muscle wasting is not fully 
understood. Majority of the evidence suggest an impairment in synthesis and 
degradation of protein and amino acid metabolism4. Protein degradation in the 
muscles is mainly mediated by the activation of the ubiquitin-dependent 
proteasome pathway19. However, calpain-dependent cleavage of myofibrils, which 
also leads to muscle wasting, acts upstream to the proteasome-dependent 








































b. Cardiac Muscle 
Cardiac atrophy is characterized by decreased heart mass mainly due to the 
combination of decreased cell size and increased apoptosis22. Cancer as well as, 
anti-cancer therapies lead to cardiac atrophy which leads to functional impairment 
of heart function. It leads to the increased burden of clinical symptoms such as 
increased breathlessness, lethargies and sometimes cardiac arrest, leading to 
mortality23,24. A study conducted by Mamidanna et al. demonstrated that about 
25.4% of colorectal patient died due to cardiac causes25. Another study comprising 
of 500 cancer patients, including gastrointestinal cancer patients, has shown that 
cardiovascular peptides (N-terminal pro BNP-N-proBNP, mid-regional pro-atrial 
natriuretic peptide-MR-proANP, mid-regional pro-adrenomedullin-MRproADM, c-
terminal pro-endothelin-1-CT-proET-1, copeptin) were upregulated in tumor-
bearing patients. Cardiopeptides concentrations were significantly correlated with 
mortality independent of age, sex and tumor stage26. Recently, a study including 
pancreatic cancer, lung cancer and gastrointestinal cancer patients along with 
healthy controls has demonstrated that body weight loss in these patients was 
accompanied with loss of heart weight27.  
Cancer-associated cardiac cachexia may be the direct consequence of 
underlying heart disease, tumor burden itself or due to the chemotherapy, 
unfortunately, the detailed molecular mechanism is not well explored23. Cancer-
associated cardiac cachexia patients exhibit reduced cardiac functions such as left 
ventricular ejection fraction (LVEF), right ventricular ejection fraction (RVEF) and 
morphological alterations such as interventricular septum thickness and posterior 
7 
 
wall thickness28. Increased level of several cardiac peptides has been reported in 
cancer patients. Increased level of BNP-NT-proBNP, MR-proANP, MRproADM, 
and CT-proET-1 were found to be correlated with survival of cancer patients26. 
Altered organization of myofibrillar proteins, disrupted and degenerated sarcomere 
has been observed in preclinical models of cancer-associated cachexia28. By 
utilizing C-26 cancer-associated cachexia model, Wysong et al. have shown that 
NF-κB inhibition exhibits cardio protective effect in tumor-bearing mice29.  
 
c. Adipose Tissue 
Cancer cachexia also entails a significant loss of white adipose tissue, which is 
attributed to an increase in lipolysis rather than a decrease in lipogenesis30,31. 
Inhibiting lipid mobilization rescued cancer-induced cachexia in mice models32. 
Although according to the 2011 consensus, skeletal muscle loss was a necessity 
for the clinical diagnosis of cancer-associated cachexia, there has been evidence 
that lipid wasting may occur before muscle wasting33,32. Therefore, the 2014 
consensus which is based on initial BMI and percentage weight loss might be a 
more accurate method to grade cachexia. 
Cachectic patients with gastrointestinal cancer have elevated levels of 
circulating free-fatty acids, triacylglycerol, and glycerol34. These fatty acids can be 
taken up by skeletal muscles and high intramuscular fatty acids can induce the 
expression of the ubiquitin ligases (Atrogin-1 and MuRF-1), leading to skeletal 
muscle atrophy35. This study was further validated by the correlation of lipid 
droplets in muscles of cancer patients with the extent of body weight loss36. A 
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recent study also demonstrated architectural modification consisting of fibrosis and 
immune cell infiltration in the subcutaneous adipose tissues in gastrointestinal 
cancer patients37. 
Another interesting phenomenon of adipose metabolism in cancer 
associated cachexia is the “browning” of white adipose tissue (WAT) , known as 
brown fat35,38. These adipocytes have high mitochondrial content and increased 
expression of the uncoupling-1 protein (UCP-1) and function like brown 
adipocytes39. UCP-1 is responsible for uncoupling the mitochondrial electron chain 
from ATP synthesis to thermogenesis40. In 2014, Petruzzi et al demonstrated that 
WAT browning is an early event and increases systemic energy expenditure in 
preclinical models of cancer-induced cachexia41. Another group demonstrated that 
upon using a genetically engineered mouse model that have reduced thermogenic 
potential and are resistant to browning, tumor-induced adipose tissue wasting was 
significantly inhibited38. Interestingly, a recent study has demonstrated that 
succinate can be metabolized by adipocytes and can induce thermogenesis, 
implying a metabolic control of this process42. 
d. Gut 
Studies have demonstrated that cachectic mice with colon cancer (APC min/+) 
undergo gut barrier disruption, which leads to increased systemic inflammation and 
plasma endotoxin concentrations43. Moreover, gut microbiota affects the host 
metabolism and immunity, two characteristics of the pathophysiology of cachexia. 
Klebsiella oxytoca is increased in cachectic C-26 bearing mice and alters the gut 
barrier function44. Lipopolysaccharide-binding protein, mostly associated with 
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bacterial load, was increased in cachectic lung and colon cancer patients45. These 
levels were also correlated with the serum IL-6 levels. Lipopolysaccharides, which 
are pro-inflammatory compounds, can induce muscle wasting through the toll-like 
receptor by activating the ubiquitin proteasome pathway and the autophagy 
lysosome pathway46. Currently, the therapeutic potential of targeting gut 
microbiota is being examined by administering prebiotics and probiotics. For 
example, adding the bacteria L. reuturi to drinking water of mice with colon cancer 
has been reported to lead to significantly increased gastrocnemius muscles and a 
statistically significant survival advantage compared to controls43. This suggests 
that cachexia may be inhibited by the introduction of advantageous bacteria. 
e. Liver 
The liver plays a key role in whole-body metabolism. In both the liver and skeletal 
muscle, an opposing pattern of protein metabolism is observed. Muscle 
degradation leads to mobilization of amino acids like alanine and glutamine; while 
glutamine is taken up by the tumor as a nutrient source, alanine is taken up by the 
liver to produce glucose by gluconeogenesis47. Cytokines have been shown to 
regulate liver metabolism by sustaining changes in the hepatic APPR (Acute 
Protein Phase Response). IL-6 is known to be the principal regulator of APPR in 
human hepatocytes48. Activation of APPR in the liver leads to hypercatabolism 
because it reprioritizes whole-body protein metabolism from skeletal muscles to 
the generation of acute phase proteins49. Production of acute phase proteins by 
the liver correlates with the mobilization of amino acids from the skeletal muscle, 
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which leads to loss of lean body mass. Further, Moses et al. found elevated APPR 
to correspond with decreased survival in pancreatic cancer patients50. 
 
3. Systemic Alterations in Cancer Cachexia 
 
In this section, we will illustrate the systemic alterations in cancer cachexia, 
which includes the inflammatory, immune and metabolic pathways (Figure 2). 
3.1 Cytokines 
A loss in muscle weight is caused by a decrease in protein synthesis and an 
increase in protein degradation. The most studied cause of muscle degradation is 
the activation of the ubiquitination pathway by pro-inflammatory cytokines (Figure 
3). A multitude of cytokines including TNF-α, IL-6, IL-1 have been implicated in 
inducing cachexia in gastrointestinal cancers51-53. The hormone “cachectin” was 
discovered by Beutler et al as a lipoprotein lipase suppressing hormone 54 and was 
demonstrated to have detrimental effects on skeletal muscles plasma membrane 
potential55. Cachectin was then recognized to correspond to the same protein as 
the human TNF-alpha56. Following that, Oliff in 1987 demonstrated that injecting 
CHO cells producing cachectin/TNF-α in nude mice killed the mice faster as 
compared to those in which the CHO cells did not secrete cachectin57. Moreover, 
it was also established that blockade of TNF-α with etanercept improved the 
tolerability of chemotherapy in patients with refractory gastric cancer58. TNF-α 
demonstrated synergy with interferon-γ in decreasing the levels of myosin heavy 







Figure 2 :  Alterations in whole body metabolism.  Tumor regulates whole body 
metabolism by releasing factors that affect the muscles, adipose deposits and the 
liver. Skeletal muscles and adipose tissues in turn secrete nutrients (amino acids 
and fatty acids) that feed the tumor. Liver associated CD68+ macrophages can 
also secrete cytokines in cachexia. Decrease in neuropeptide Y in the brain can 










bearing mice. This study also established that myosin heavy chain was a target of 
the pro-cachectic factors59. 
There was an increased level of circulating cytokines (IL-6, IL-α, TNF-α) in 
the serum of colon and pancreatic cancer patients suggesting a network of 
cytokines collectively promoting cachexia60. Elevated levels of IL-6 in serum of 
pancreatic cancer patients was associated with decreased muscle mass and 
severe fatigue51. Circulating levels of IL-6 also have been demonstrated to be 
elevated in the plasma of spontaneous mouse models of colon cancer which led 
to loss in body weight53. Another study by the same group also established that 
deleting IL-6 not only abrogated cachexia but also led to reduced tumor burden in 
the colon cancer mouse model61. 
The myosin differentiation factor, MyoD1, which binds to the promoter of 
myosin heavy chain is regulated by these cytokines.  The cytokines TNF-α and IL-
6 activate the p38 MAPK and the NFκB pathways which are needed to upregulate 
the E3 ligases MURF1 and MAFbx ,  which modulate breakdown of sarcomeres 
and inhibition of protein synthesis62. MURF1 is responsible for modulating the 
ubiquitination of the myosin heavy chain and other thick filaments 63,64. The MURF1 
and MAFbx family of proteins are regulated by the Forkhead box proteins, namely 
Foxo3, Foxo1 and Foxo465. Furthermore, it was also demonstrated that the 
injection of double negative foxo in the skeletal muscles of mice before 
implantation of tumor cells reduced the mRNA levels of MAFbx and MuRF1, further 







Figure 3 : Cytokines regulate muscle wasting factors.   Immune cells and tumor 
cells can release cytokines which affects both the liver and the skeletal muscles. 
This can induce acute phase protein response in the liver. Cytokines can also 
induce the liver to release c-reactive protein (CRP) into the blood vessels. Cytokine 
released from the liver can also stimulate proteolysis in the skeletal muscles via 
the activation of NF-κB. Activation of NF-κB can induce the transcription of the 
muscle specific ubiquitin ligases- muscle ring finger containing protein-1 [MURF1] 
and muscle atrophy F box protein [MAFbx]. Amino acids like glutamine and alanine 









A TGF-β family member, myostatin has been implicated in inducing cachexia. 
Genetic null mutations for myostatin in humans and animals demonstrated muscle 
hypertrophy67,68. Myostatin is mainly synthesized and secreted from the skeletal 
muscle cells and function via the activin type IIb (ActRIIB) receptor. Although the 
exact mechanism is still unclear, studies suggest that there might be multiple 
pathways that act by inhibiting AKT and thus the downstream TORC1 pathways 
which promote protein synthesis69,70. Inhibition of ActRIIB prevented muscle 
wasting and prolonged survival in C-26 colon tumor-bearing mice17. A myostatin 
inhibitor, BYM338 is currently in the phase 2 trial for attenuating body weight loss 
in stage III/IV pancreatic cancer patients (ClinicalTrials.gov. Clinical study of 
BYM338 for the treatment of unintentional weight loss in patients with cancer of 
the lung or the pancreas). A humanized anti-myostatin antibody, LY2495655 is the 
phase 2 trial in combination with gemcitabine to evaluate its efficacy in improving 
survival and lean body mass in patients having advanced or metastatic pancreatic 
cancer. (ClinicalTrials.gov. A Phase 2 study of LY2495655 in participants with 
pancreatic cancer). 
3.3. Proteolysis Inducing Factor 
Proteolysis inducing factor (PIF) is produced by murine and human tumors. 
Immunohistochemistry has demonstrated the presence of PIF in the cytoplasm of 
gastrointestinal cancers and a correlation was established between its expression, 
detection in the urine and weight loss71. In another study, PIF was detected in 80% 
of pancreatic cancer patients who suffered greater significant weight loss and had 
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increased rate of weight loss than patients who didn’t have PIF in their urine72. It 
has been reported that this factor leads to increase in protein degradation and a 
decrease in protein synthesis73. Interestingly, when PIF was isolated from the urine 
of cancer patients including pancreatic and colon, and injected into  mice, it led to 
induction of cachexia, without reduction in food or water intake74. Unlike the 
cytokines mentioned previously, PIF can act on isolated skeletal muscle and can 
generate a state of cachexia in non-tumor bearing model without a decrease in 
food intake75. In addition, administration of PIF to normal mice upregulated the 
ubiquitin proteosomal pathway, indicating this as one of the mechanisms of action 
of PIF76. These results were also validated in cell culture conditions with murine 
myotubes. In the murine myotubes, addition of PIF inhibited the inhibitor of NF-κB, 
which is IκBα. This resulted in more NF-κB entering the nucleus and an increased 
expression of the regulators of the ubiquitin- proteosomal proteolytic pathway77. 
Moreover, activation of NADPH oxidases and reactive oxygen species (ROS) also 
play a role in PIF-induced expression of ubiquitin-proteosomal pathway which 
leads to muscle degradation78,79. Increased ROS again leads to the degradation 
of IκBα, which releases NF-κB from its inactive state78. 
Although there has been a lot of evidence of inflammatory pathways being 
involved in cachexia in preclinical models, the clinical trials with anti-inflammatory 





3.4. Insulin-like growth factor (IGF-1) 
In recent years, the role played by insulin-like growth factor-1 (IGF-1) has been 
evaluated in the context of cancer-cachexia. It has been established that IGF-1 
stimulates muscle protein synthesis, differentiation and proliferation of satellite 
cells80. It mainly acts on the PI3K pathway which activates the downstream targets 
which are required for protein synthesis81. It was observed that rats bearing 
Yoshida AH-130 ascites hepatoma suffered from muscle atrophy which was 
associated with decreased IGF-expression in the skeletal muscle. As a suggested 
adaptive mechanism, skeletal muscles also demonstrated an increase in the levels 
of the IGF-1 receptor82. Moreover, muscle wasting was rescued by the 
administration of insulin but not IGF-1, possibly due to its low bioavailability82. In a 
separate study, mouse models of colon adenocarcinoma and hepatoma 
demonstrated that the cachectic tumor-bearing mice had decreased mRNA levels 
of IGF-1 in the skeletal muscles. However, there was no difference in the activation 
of the PI3K pathway suggesting that some other pathways might be responsible 
for IGF-1-induced muscle wasting83. 
3.5. Oxidative Stress  
Reactive oxygen species are highly unstable and short-lived molecules that play a 
major role in signaling and physiological pathways. Increase in oxidative stress is 
another characteristic of cachexia/anorexia. In rats bearing Yoshida AH-130 
hepatoma, there was an increased levels of total protein carbonylation in the 
cachectic skeletal muscles84. This increase in oxidative modification was not 
compensated by an increase in the antioxidants, which might be a reason for 
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increased oxidative stress in cancer-induced cachexia84,85. It has also been 
reported that mice implanted with Chinese hamster ovary cells transfected with 
TNF-α become cachectic and lead to an increase in oxidative stress and nitric 
oxide synthase in the skeletal muscles. This lead to a decrease in the myosin 
creatine kinase which is needed for muscle differentiation86. Oxidative stress has 
also been reported to activate NF-κB which regulates the ubiquitin proteasome 
pathway87. Moreover, it has been demonstrated that hydrogen peroxide induces 
ubiquitin conjugation to proteins through the transcriptional regulation of the E2 
and E3 enzymes in mice C2C12 myotubes88. In 2007, Russell et al suggested that 
PIF and angiotensin can upregulate the ubiquitin proteasome pathway by ROS 
produced by nicotinamide adenine dinucleotide phosphate (NADPH) oxidases 
(Nox) in murine myotubes79. In the skeletal muscles of cachectic tumor-bearing 
mice (MAC-16), there was an increase in Nox4 which generates hydrogen 
peroxide and a decrease in antioxidants such as glutathione peroxidases, 
catalases and superoxide dismutases85. 
3.6. Impaired regeneration of muscle fibers  
Muscle atrophy can not only be associated with increased muscle proteolysis, but 
also decreased muscle regeneration or differentiation. Expression of Pax7, a 
marker of muscle satellite cells was demonstrated to be increased in the skeletal 
muscles of C-26 bearing mice. Sustained expression of Pax7 results in muscle 
progenitors being in a state of self-renewal which results in impaired differentiation 
and inhibition of fusion. This is also indicated by decreased levels of MyoD, which 
is a downstream target of Pax789. Moreover, adenovirus overexpression of MyoD 
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in skeletal muscles of tumor-bearing mice rescued muscle wasting89. Pax7 was 
also reported to be increased in the muscles of cachectic gastric cancer patients90. 
MyoD is also demonstrated to be inhibited by the pro-inflammatory cytokines such 
as TNF-α via NF-κB signaling91.  
3.7. Appetite and Adipose Tissue Loss 
A major aspect of cancer patients is the loss in appetite, which in turn may lead to 
anorexia. Studies have demonstrated that about 50% of patients confirm 
irregularities in their food habits at diagnosis92. Anorexia is differentiated from 
cachexia, in the way that in anorexia there is a decreased interest to eat which 
may lead to decreased food intake. Cachexia is the loss of adipose and muscle 
mass which leads to hypoalbuminemia and asthenia that limits patient’s physical 
activity and inhibits protein synthesis93. Cachexia is dissimilar from starvation as 
there is preservation of lean body mass in starvation. Cancer patients suffer from 
both anorexia and cachexia, though the loss in body weight cannot be attributed 
to decreased food intake. This was further validated by studies demonstrating 
muscle wasting even in the presence of normal food intake94. Moreover, it has also 
been observed that administration of food and nutrients are unable to reverse the 
muscle wasting95.  
Along with skeletal muscle wasting, cancer cachexia entails a significant 
loss of white adipose tissues. This loss has been attributed to an increase in 
lipolysis rather than a decrease in lipogenesis30,31. Cachectic patients with 
gastrointestinal cancer have elevated levels of circulating free fatty acids, triacyl 
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glycerol and glycerol34. Some studies have also implied the loss in WAT precedes 
the loss in muscle mass33.  
3.8. Adipokines 
Leptin is one of the major hormones associated with appetite. It decreases food 
intake and increases energy expenditure.  It was the first hormone to be discovered 
which is secreted from adipocytes. It can cross the blood-brain barrier96 and has 
its receptors at the hypothalamus. Its receptors are also present peripherally at the 
skeletal muscles, pancreatic islet cells, kidneys and some other tissues97. Along 
with adipocytes, leptin has also been observed to be secreted by the gastric and 
epithelial tissues98. There have been conflicting reports on the serum level of leptin 
in cachectic cancer patients. One study reported that serum leptin levels are 
observed to be decreased in patients with gastric cancer as compared to the 
normal healthy control but there was no significant difference in cachectic and non-
cachectic patients99. Another study demonstrated that cachectic gastric cancer 
patients had significantly higher level of serum leptin than the non-cachectic 
patients; and a negative correlation was found between leptin levels and BMI9. 
There is also a definite crosstalk between leptin signaling and inflammation. 
During fasting, leptin levels decrease and then again increase during the 
postprandial phase. When fasted hamsters were treated with TNF-α and IL-1, they 
showed an increased levels of leptin mRNA in the adipose tissues100. This increase 
in leptin was correlated with a decline in food intake. The cross talk between the 
leptin and the inflammation pathways have also been demonstrated in studies 
wherein peripheral leptin administration caused hypothalamic inflammation and 
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central injection of IL-1 receptor (IL-1r) antagonist inhibited the suppression of food 
intake caused by central or peripheral injection of leptin101,102.  
Another important hormone associated with cachexia is the adipokine 
called adiponectin. Adiponectin is specifically released by adipose tissues. There 
is an inverse correlation between adiponectin and obesity and levels of adiponectin 
increases with weight loss103. Serum levels of adiponectin is increased in cachectic 
colon cancer patients104. In contradiction, reports have also shown association of 
low levels of adiponectin to increased risk of gastric cancer105. An explanation for 
this might be that TNF-α inhibits the secretion of adiponectin from adipocytes106,107.   
It has also been demonstrated that adiponectin is increased in the cases of cardiac 
cachexia irrespective of the body mass index. Adiponectin regulates the activity of 
ceramidase which removes acyl chains from ceramides. Ceramides are related to 
inflammation and insulin resistance108. In other studies, administration of 
adiponectin, increased the molecules which are involved in fatty acid transport and 
energy consumption such as acyl-coA oxidase and uncoupling protein-292.These 
molecular processes decreases the tissue triglyceride content in skeletal muscles. 
3.9. Ghrelin 
Ghrelin, a natural ligand for the growth hormone receptor secretagogue receptor 
(GHS-R) that is produced in the fundus of the stomach, is another important that 
plays a key role in cancer cachexia109. However, ghrelin is shown to stimulate food 
intake and adiposity by a GH-independent mechanism110. Counterintuitively, 
patients with cancer and cardiac cachexia have increased circulating 
concentrations of ghrelin, perhaps due to negative energy balance104,111. Even in 
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such cases, ghrelin administration resulted in an increase in food intake112,113. 
Studies have also demonstrated that Ghrelin decreases serum levels of IL-6. 
Considering the role of inflammation in cachexia, this might be another mechanism 
by which ghrelin can improve cachexia. However, it is not clear if all these 
hormones play critical roles in cachexia in tumors of different origins. 
3.10. Neuronal Regulation 
Cachexia is mostly also associated with decreased food intake and change in taste 
perception4. These are characteristics of anorexia which worsens the 
manifestation of cachexia. It has been reported that both orexigenic (appetite-
stimulating) and anorexigenic (appetite-suppressing) pathways are altered in 
cancer patients114. Increase in cytokines can  activate  anorexigenic pathways and 
inhibit orexigenic pathways leading to the decrease of neuropeptide Y and thus 
decrease in appetitie114. The melanocortin system can also participate in the 
process of muscle wasting. Thus, in a mouse model of colon cancer, melanocortin 
receptor antagonist abrogated muscle depletion115. 
3.11. Lipid Mobilizing Factor (LMF)/Zinc alpha 2 glycoprotein (ZAG)  
The search for a tumor-secreting product having lipid mobilizing activity led to the 
purification of a 43 kDa glycoprotein from the cachexia-inducing MAC16 tumor116. 
Zinc α2 Glycoprotein (ZAG) acts as a lipid mobilizing factor and is overexpressed 
in certain malignant tumors117. ZAG has been reported to be present in the urine 
of cachectic pancreatic cancer patients but not non-cachectic cancer patients116. 
Moreover, a study also established the possibility of utilizing serum levels of 
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ZAG/LMF as a biomarker for pancreatic cancer cachexia. Expression of ZAG was 
also observed more in pancreatic cancer tumors of cachectic patients  than non-
cachectic patients upon immunohistochemical analysis118. LMF/ZAG can directly 
activate adenylyl cyclase in a GTP dependent process; thereby inducing 
lipolysis119. It has been shown that administration of ZAG to mice reduces body fat 
and induces hormone sensitive lipase (HSL)120. In 2004, Trayhurn and colleagues 
demonstrated that ZAG is also expressed in white adipose tissues (WAT) and is 
observed to be overexpressed in adipocytes of MAC16-bearing cachectic mice 
121.ZAG is also expressed in brown adipose tissue (BAT) in cachectic mice, which 
is required for lipid utilization121. Thus, BAT increases energy utilization by 
generating heat instead of ATP in cachectic mice by upregulating BAT UCP1 
mRNA, via ZAG. 
3.12. Triglyceride Lipases 
White adipose tissue (WAT) is the reservoir for triaclyglycerides (TAG). The TAGs 
in the WATs are broken down by adipose triglyceride lipase (ATGL), in a rate 
limiting step to form diacyl glycerides (DAGs). The DAGs are broken down by 
hormone sensitive lipase (HSL) to form monoacylglycerols (MAGs), which is 
further broken down into free fatty acids and glycerol by monoglyceride lipases 
(MGL). Many factors regulate these lipases which lead to increase or decrease of 
lipolysis. In cancer cachexia, there is evidence of decrease in TAGs in WAT rather 
than complete cell death. The levels of HSL were reported to be two-fold higher in 
the WAT of cancer patients as compared to the control group122. HSL is activated 
by its phosphorylation which is modulated by protein kinase A, extracellular signal-
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regulated kinase (ERK), glycogen synthase kinase 3β (GSK-3β; previously known 
as GSK-4), calmodulin-dependent kinase II (CAMKII), as well as AMP-activated 
protein kinase (AMPK)123,124. It was demonstrated that the ATGL activity is 
increased in murine cachexia models with increase in tumor burden and WAT 
mobilization32. ATGL knockout mice showed protection from tumor induced 
lipolysis. Moreover, cachectic cancer patients showed significantly increased 
ATGL activity in their WAT tissues32. In addition, ATGL is also observed to be 
expressed in skeletal muscles and reported to play an important role in lipid 
metabolism in muscles125. HSL activity and expression in skeletal muscles is also 
reported to lead to insulin resistance126. 
3.13. Insulin Resistance 
Glucose intolerance was the first metabolic abnormality that was recorded in 
cancer patients127. The main hormone to control blood glucose levels is insulin, 
which plays a major role in whole body metabolism including fat, amino acid and 
protein metabolism. Consumption of a meal triggers the release of insulin from 
pancreatic beta cells which decreases circulating blood glucose levels. This 
happens due to the action of insulin on muscles and fat deposits which makes 
these tissues utilize glucose thereby decreasing its concentration in the blood.  
In 1965, one of the earliest large scale studies to report metabolic effects of 
cancer, including cancer of the GI tract, in patients demonstrated a significant 
percentage of cancer patients suffering from glucose intolerance or diabetes128. It 
has been reported that there is a high incidence of glucose intolerance in 
pancreatic cancer patients, which cannot be explained by impaired secretion of 
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insulin129. Furthermore, it has also been demonstrated that insulin infusions into 
skeletal muscle increases amino acid uptake and reduces proteolysis130. Higher 
doses of insulin infusions decrease the blood glucose levels but have no effect on 
protein mass130 .Therefore, there is evidence that insulin affects skeletal muscle 
mass and alterations in the levels of insulin can perturb proteolysis. 
There has also been evidence regarding the development of glucose 
intolerance before the manifestation of cancer. Norton and his colleagues 
demonstrated that in 27 otherwise healthy patients with localized sarcoma, glucose 
intolerance occurred before other signs of cachexia appeared131. Furthermore, in 
the said cohort, those patients who had less than ideal body weight showed lower 
glucose tolerance than the other patients. These studies indicate the role of 
glucose tolerance and insulin sensitivity in muscle wasting in cancer patients. Mice 
bearing colon-C26 adenocarcinoma demonstrated a blunted blood glucose 
response to insulin in an insulin tolerance test before a difference in body weight 
was observed. This suggested that insulin resistance is an early event in the 
development of cancer cachexia132. One of the factors identified for impaired 
insulin signaling is TNF-α, which is observed to decrease the autophosphorylation 
of the insulin receptor(IR) and the IR substrate 1133.  
The insulin signaling pathway overlaps with the ubiquitin proteolytic 
pathway. Insulin binding to its receptor activates the PI3K and AKT. AKT 
suppresses FOXO3 and caspase-3 activation, thus decreasing the expression of 
the muscle ubiquitin ligases atrogin-1 and murf-1. However, in cancer cachexia, 
when patients suffer from insulin resistance, the suppression of PI3K and AKT is 
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decreased and there is an increased expression of the components of the ubiquitin 
proteolytic pathway. This  is one mechanism through which insulin resistance can 
control muscle degradation134. Insulin resistance might fuel tumor growth in two 
possible ways – first, by promoting muscle wasting and thus mobilizing amino 
acids into circulation; second by promoting liver gluconeogenesis135 which would 
increase REE, tissue wasting and would fuel cancer aerobic glycolysis. 
3.14. Fatty Acid Oxidation 
Cancer cell-secreted inflammatory factors can lead to increased fatty acid 
metabolism and p38 stress signature in the muscles136. Moreover, 
pharmacological blockade of fatty acid oxidation improves muscle mass and body 
weight in vivo136. 
The metabolic capacity of skeletal muscles is a substantial characteristic in 
the pathophysiology of cancer cachexia. Muscle fiber subtypes are traditionally 
delineated by the isoform of myosin heavy chain (MHC) expressed (eg. slow 
twitch- type I; fast twitch- type IIA, IIB, and IIX) that impacts the metabolic 
phenotypes and mitochondrial capacity137. Myogenesis tends to alter the metabolic 
profile from a glycolytic phenotype toward a greater dependency on oxidative 
phosphorylation138. MHC subtype I and IIA containing isoforms most heavily rely 
on oxidative metabolism, and MHC type IIB and IIX are highly glycolytic139. The 
rate of protein synthesis is greater in the oxidative muscle fibers as compared to 
the glycolytic ones140. Of note, multiple mice models of cancer cachexia display 
the loss of the oxidative phenotype141. Extrapolating this evidence, there are also 
studies which demonstrate decreased protein synthesis in mouse models of 
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cancer cachexia142. While it is not known if muscle wasting leads to changes in 
MHC subtypes, metabolic profiling studies indicate decreased overall glycolytic 
capacity. 
3.15. Mitochondrial biogenesis and dynamics 
Dynamic mitochondrial networks fulfill the energy demands of different cells and 
play a very important role in cellular physiology. Due to the high energy demands 
in muscles, mitochondria, the cellular energy factories, play a significant role in 
muscle physiology and pathologies143. Dysregulation of mitochondrial biogenesis 
and dynamics regulates muscle mass and physiology by regulating different 
molecular and signaling events144,145. Recently, Brown et al., have shown that 
mitochondrial degeneration precedes the muscle atrophy in murine models of 
cancer-associated cachexia146. Several published studies and genome-wide 
dataset analysis from different animal models of cancer-associated cachexia have 
revealed altered expression of genes involved mitochondrial biogenesis and 
dynamics147. 
Skeletal muscles from cancer patients display significant alterations in the 
expression of genes involved in mitochondrial dynamics. A study involving 18 
patients of gastric adenocarcinoma (nine cachectic and nine non-cachectic) along 
with 9 healthy controls, showed altered expression of mitochondrial dynamics 
genes. Cachectic cancer patient muscles displayed reduced expression of FIS1 
fission protein, and lipidated and non-lipidated forms of LC3B148. ApcMin/+ mouse 
model of colon cancer-associated cachexia also displays altered expression of 
proteins regulating mitochondrial dynamics, including PGC1-α and mitofusins 
27 
 
(Mfn1, Mfn2), even before changes in mitochondrial mass are apparent at the early 
stages of muscle wasting149. However, with the progression of the cachectic 
phenotype these mice exhibit the loss of mitochondrial content with decreased 
expression of PGC1-α and mitofusins, and increased expression of Fis1149. C-26 
tumor-bearing mice, another model of colon cancer-associated cachexia, present 
reduced expression of PGC1-α, TFAM, and TOM20 in skeletal muscles, which 
correlates well with the reduced cross-sectional area of gastrocnemius muscles 
and increased expression of cachectic markers150. C-26 tumor-bearing mice 
skeletal muscles also exhibit distorted mitochondria, impaired oxidative capacity, 
and reduced ATP regeneration that may significantly impact the contractile 
function and predispose the mice to muscle wasting151. Altered mitochondrial 
biogenesis and dynamics leads to bioenergetic insufficiency and increased 
oxidative stress due to generation of reactive oxygen species (ROS). Reduced 
oxidative capacity, altered protein synthesis and membrane fluidity, and post-
translationally-modified mitochondrial proteins altogether hampers the 
mitochondrial function in cachectic muscles4. While a few preclinical cachexia 
models have evaluated alterations in mitochondrial homeostasis, the broad scope 
of mitochondrial biogenesis and dynamics in gastrointestinal cancer-associated 
cachexia in patients is still underexplored. More clinical and preclinical studies 
under relevant physiological conditions can significantly improve our 






3.16. Zinc Metabolism 
Cachectic muscles in patients and animal models display significant accumulation 
of zinc152. Animal models with fibrosarcoma, lewis lung carcinoma, and murine-
adenocarcinoma demonstrate accumulation of zinc in the cachectic skeletal 
muscles153. Siren et al. hypothesized that though zinc homeostasis is normally 
tightly regulated, during inflammation, infection, or cancer zinc dyshomeostasis 
can occur via an acute phase protein response (APPR)152. Regarding the potential 
mechanisms of zinc accumulation in cachectic muscles, zinc transporters are 
induced in cachectic muscles. The cachectic cytokine IL-6 regulates the zinc 
transporter (Zip14) in the liver which contributes to the hypozincemia during 
APPR154. Furthermore, due to the critical role of zinc in immune regulation, altered 
zinc metabolism can also contribute to systemic inflammation as observed in 
cachexia155. Recently, Wang et al. also demonstrated an upregulation of ZIP14 in 
the cachectic muscles of metastatic cancer models156. Transforming growth factor 
beta (TGF-β) and TNF-α mediated the induction of ZIP14 expression in the 
muscles of these models. ZIP14- mediated Zn accumulation also blocked muscle 
differentiation, along with decreased levels of myosin heavy chain156.  
4. Immunological aspects of GI cancer-induced cachexia 
 
The immunological status of the host body is a major determinant in progression 
of cancer and cachexia. Studies have demonstrated a strong decline in contact 
hypersensitivity, a parameter for cell-mediated immunity, in C26 tumor-bearing 
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cachectic mice157. Interestingly, this decline was observed even before the mice 
underwent weight-loss, therefore implicating the importance of immunity in the pre-
cachectic state. Cachectic pancreatic cancer patients also had an increased 
infiltration of activated macrophages in the liver as indicated by CD68 
immunoreactivity158. The amount of IL-6 staining in hepatocytes surrounding the 
CD68-positive macrophages was significantly increased in cachectic pancreatic 
cancer patients as compared to non-cachectic patients, indicating that liver 
parenchymal cells may be triggered by macrophages to produce pro-inflammatory 
cytokines like IL-6158. 
5. Chemotherapy-induced cachexia in gastrointestinal cancers 
 
Anti-tumor cytotoxic agents have several deleterious impacts on normal tissues 
and physiology159 (Table 1). Chemotherapeutic agents have been shown to exhibit 
pro-inflammatory properties160,161 and deregulate nitrogen metabolism of the host 
body162. Chemotherapeutic agents such as cisplatin, FOLFOX (5-FU, leucovorin, 
oxaliplatin), FOLFIRINOX (5-FU, leucovorin, irinotecan) , doxorubicin and 
sorafenib contribute to myopathy independent of their anti-tumor effect in 
preclinical models of cancer-induced cachexia163,164,165,166,167. Recently it has also 
been shown that muscle wasting is associated with long term use of mTOR 
inhibitors168. In a longitudinal study of colorectal cancer patients with metastasis, it 
was observed that muscle area decreased significantly during combination of 
capecitabine plus oxaliplatin with or without bevacizumab treatment and it was 
independently associated with survival in patients169. Similarly, Eriksson et al., 
have reported that muscle mass decreases during neoadjuvant chemotherapy in 
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patients with resectable colorectal liver metastases170. Gemcitabine, the first line 
standard of care for pancreatic cancer has been shown to induce muscle atrophy 
in a mouse model of pancreatic cancer171. 
Molecular mechanism of chemotherapy-induced muscle wasting varies 
widely. Chemotherapy-induced alteration of ROS homeostasis plays important 
role in muscle weakness and fatigue172. FOLFOX has been shown to induce 
muscle atrophy by activating ERK1/2 and p38MAPKs signaling pathways in 
addition to modulating mitochondrial biogenesis163. Widely used anti-cancer agent 
doxorubicin induces muscle atrophy by altering calcium homeostasis of muscle 
and inducing autophagy165,173. Doxorubicin also modulates TNF1R activity in 
skeletal muscles174. Furthermore, it has been shown that doxorubicin treatment 
results in hyperglycemia and insulin resistance which is mainly mediated by 
negative regulation of AMPK signaling pathway in mice muscles175. Baretto et al. 
have demonstrated that chemotherapy -induced muscle wasting and cancer-
induced muscle atrophy share common alterations in signaling pathways176. 
Modulation of glucocorticoid receptor mediated signaling has been reported to play 
an important role in 5-FU mediated muscle atrophy in murine skeletal muscles177. 
Only a few pre-clinical studies have explored the therapeutic options to manage 
chemotherapy-induced cachexia. It has been shown that ACVR2B/Fc prevents 
FOLFRI mediated muscle loss178. Mirtazapine, an antidepressant drug has shown 
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6. Regulation of muscle atrophy by microRNAs 
 
MicroRNAs (miRNAs) are short noncoding RNAs which play an important role in 
post-transcriptional gene regulation, thus affecting several key biological 
processes including muscle atrophy179. Recently Narsimnhan et al. have shown 
that several miRNAs are differentially expressed in skeletal muscles of cachectic 
verses non-cachectic pancreatic and colorectal cancer patients180. They observed 
that miR-3184-3p, miR-1296-5p and let-7d were significantly upregulated in the 
muscles of cachectic patients180. Moreover, it has been shown that miR-378 
regulates lipolysis in gastrointestinal cancer patients181. Pancreatic tumor-derived 
microvesicles containing miR-21 induces myotube atrophy by inducing apoptosis 
through TLR activation182. miR-21 has been also shown to be upregulated in 
denervation induced muscle atrophy and it regulates translational initiation 
process183. Overall, these evidences suggest that several miRNAs regulate 
muscle atrophy and lipolysis in gastrointestinal cancer-induced cachexia. 
7. Serum Metabolic Profile 
 
Recent studies have demonstrated distinct metabolic profiles in cachectic cancer 
patients compared to non-cachectic cancer patients184. Cancer patients with 
cachexia presented decreased glucose and elevated lactate in the serum, 
compared to the non-cachectic ones. Metabolomic profiling identified 45 
distinguishing metabolites and 18 metabolic pathways that were associated with 
cachexia. Out of the 45 metabolites, logistic regression analysis revealed 
diagnostic potential of a three-metabolite signature, consisting of carnosine, 
phenylacetate, and leucine. Similar metabolic alterations have been observed in 
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mice sera185. In addition to the metabolic changes observed in the serum 
specimens, gastrocnemius muscle specimens from murine cancer cachexia 
models also reflect metabolic changes associated with wasting185. Of note, that the 
common metabolic changes between human and the murine model included 
leucine, phenylacetate, and carnosine. 
Another study utilizing a cohort of 390 cancer patients demonstrated that 
49% of the patients had hypermetabolism which was associated with clinical and 
biological features of precachexia186. Hypermetabolism also correlated with 
decreased survival in metastatic cancer patients187. 
8. Metabolic Alterations in the Tumor  
 
Altered metabolism is a known hallmark of cancer cells (Figure 4). Under normal 
conditions, metabolic pathways are highly regulated, but once the cells undergo 
malignant transformation due to the induction of oncogenes or suppression of 
tumor suppressors, tumor cells reprogram the metabolic pathways to need their 
growing cellular requirements188. The metabolic pathways that majorly get 
reprogramed is glycolysis, glutaminolysis and fatty acid synthesis. Recent studies 
by our laboratory have demonstrated that pancreatic cancer patients on 
chemotherapy who had a higher PET signal had poor prognosis, suggesting that 





Figure 4 : Metabolic alterations in tumor and serum.  Metabolic alterations in 
tumor, distinct uptake and release of metabolites from the tumor and its uptake in 
the muscles regulate muscle wasting.  
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Extrapolating this evidence, it can be hypothesized that different tumors can have 
different metabolic alterations which can affect patient prognosis and survival.  
Several reports have demonstrated that specific metabolite uptakes are required 
for tumor progression, for example glutamine190, serine191, branched amino acids 
and lipids192 in cancers including gastrointestinal cancers. Interestingly, in 2014 
Mayers et al profiled the prediagnostic plasma metabolite levels of patients with 
pancreatic cancer and observed an increased level of branched chain amino acids 
as compared to the plasma of control cohorts193. This suggests that whole-body 
protein break down occurs even before the cancer is diagnosed in patients. 
Furthermore, Luo et al identified metabolic cross talk occurring between colorectal 
cancer and skeletal muscles. It was demonstrated that colorectal tumors release 
high-motility group box 1 (HMGB1) which leads to the metabolic reprogramming 
of skeletal muscle through RAGE (Receptor for Advanced Glycation End-products) 
by inducing autophagy and release of free amino acids in the plasma (Figure 5). 
13C tracing experiments confirmed the transfer of carbon skeleton from the 
muscles to the tumor. 
Cachexia has also been shown to be associated with hypoalbuminemia194. 
But this condition was shown to be independent of functional capacity of the liver 
and, in turn, was said to be related to increased protein breakdown or increased 
utilization of protein by the tumor. It was also demonstrated that insulin releasing 
compounds, like glucose, failed to release insulin in cachectic rats195. This study, 
along with their own, led Jasani and colleagues to conclude that in order to combat 
cachexia it is not only essential to improve dietary protein intake but also reduce 
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the metabolic activity of the tumor tissue194. Since only protein replenishment has 
served to be effective in non-malignant cachexia, combating the metabolic 
activities of the tumor tissue is crucial. 
9. Advances Made in Altering Metabolic Pathways 
 
Cachexia, till date has no FDA approved therapies. In the clinic, cachexia is 
managed by nutritional supplements or hormones to increase appetite. In research 
labs, attempts are being made to evaluate compounds which can target the tumor 
and combat muscle wasting (Figure 6). 
a. Ketone Bodies and Fenofibrate 
It has been demonstrated by Shukla et al in 2014 that a ketogenic diet leads to 
diminished glucose flux in the pancreatic cancer cell lines196. This also reduced 
glutamine uptake, ATP content and reduced survival in pancreatic cancer cell lines 
while inducing apoptosis. The metabolic reprogramming of pancreatic cancer cell 
lines reduced cachexia in the cell line model.  This was further confirmed in mouse 
xenograft models. Hence, following a ketogenic diet might be a successful strategy 
to combat cachexia. 
A unique metabolic gene signature in a murine model of cancer cachexia, which 
involved losing the peroxisome proliferator-activated receptor-α (PPARα)-
dependent ketone production in the liver, was also reported197. There was a rise 
of glucocorticoid levels which correlated with degeneration of muscle fibers and 
increased hepatic gluconeogenesis. This loss in skeletal mass could be prevented 


















Figure 5 : Tumor cells secrete factors which degrade skeletal muscles. 
HMGB1 is released from the tumor cells and is shown to inhibit the conversion of 
phosphoenolpyruvate (PEP) to pyruvate.  This can inhibit the TCA cycle in 
muscles. HMGB1 can also induce autophagy in muscles, which can increase 
proteolysis leading to the generation of glutamine. Glutamine can be taken up by 













b. Silibinin  
Silibinin is a natural product which has been demonstrated to have anti-cancer 
properties. Our lab demonstrated that silibinin successfully reduced the growth of 
pancreatic cancer cells by reducing glycolytic flux198. Moreover, it was also 
demonstrated that silibinin reduces tumor growth and proliferation in an orthotopic 
mouse model of pancreatic cancer and prevents loss of body weight and muscle 
mass. 
c. Etomoxir 
In recent studies, Fukawa and colleagues reported that factors released by 
cachectic cancer cell lines induce fatty acid oxidation in human myotubes, which 
lead to oxidative stress, p38 activation and impaired muscle growth136. Moreover, 
pharmacological blockade of fatty acid oxidation by administration of etoxomir not 
only prevented human myotube degradation but also improved muscle mass in 
murine models of cancer cachexia136. 
d. Antioxidants  
Since oxidative stress-induced modifications are an important part of muscle 
wasting, antioxidants are being tested for their efficacy in combating cancer- 
cachexia. It was reported that D-alpha-tocopherol, an antioxidant was successful 
in combating muscle wasting in a murine model of cancer cachexia by decreasing 






Figure 6 : Targeting tumor metabolism in order to combat cachexia.  Tumor 
metabolism can be altered by ketone bodies which inhibits glycolysis, by etoxomir 
which blocks fatty acid oxidation or by silibinin which inhibits c-myc thereby 
inhibiting transcription of glycolysis genes. Antioxidants can directly affect the 
muscles by reducing reactive oxygen species related damage, which can then 
inhibit the transcription of ubiquitin ligases.
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10. Potential for new therapeutic approaches 
 
Although a lot is known about the mechanisms of cachexia development, most of 
the therapies which includes anti-inflammatory drugs, nutrition support, hormonal 
supplements have not given promising results in clinical trials199. As mentioned in 
this chapter, because cachexia is a product of inflammatory and metabolic 
alterations, a combination of drugs targeting both these pathways looks most 
promising. Since chemotherapy can also aggravate muscle wasting, compounds 
which combat muscle wasting can be administered along with chemotherapeutic 
drugs to ameliorate the effect of chemotherapy on the muscles. This is not a trivial 
pursuit since it is important to not decrease the efficacy of the chemotherapeutic 
drug by its combination with chemoprotectant drugs. 
11. Conclusion and Perspectives 
 
It has been three decades since the discovery of “cachectin”, and yet there has 
been no promising therapeutic approach to combat cachexia. As previously 
mentioned, cachexia is more than just a wasting disease; it reduces the patient’s 
ability to receive or respond to therapy and decreases survival. It is a multifactorial 
syndrome that is associated with anorexia and hyper catabolism due to pro-
inflammatory cytokines, hormones, neuronal peptides, tumor-derived factors and 
altered tumor metabolism. A lot of research is still required to target these factors 
together in a multimodal therapeutic approach. This is challenging since each 
tumor varies genetically and metabolically and a common approach might not be 
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effective for all patients. This suggests that there is a need for the development of 
personalized medicine to combat cancer and also mitigate cachexia. 
12. Goals of the Dissertation  
 
The aim of this dissertation is to elucidate novel mechanisms involved in the 
manifestation of pancreatic cancer-cachexia. To this end, we utilized spontaneous 
pancreatic cancer mouse models, pancreatic cancer patient muscle samples and 
in-vitro models of muscle atrophy. Chapters 3 and 4 illustrate the role of Sirt1-Nox4 
axis in inducing cachexia and Chapter 5 investigates the role of chemotherapy in 

















Chapter 2: Methods and Materials 
 All the chapters of this dissertation are majorly focused on methods involving 
muscle wasting. Since most of the projects utilize similar methods, they are 
described in this section: 
Cell Culture and Reagents 
Pancreatic cancer cell lines T3M4 and S2-013 were generous gifts from Dr. 
Michael A. Hollingsworth200. Cell lines were validated by STR profiling by the 
Genetics Core at Arizona University. Mouse pancreatic cancer cell lines (KPC 
1245, 1199 and 242) were derived from the transgenic mice models described 
below. Colon cancer cell line C26 was obtained from ATCC. All cell lines were 
cultured in Dulbecco's Modified Eagle Medium (DMEM) (Sigma-Aldrich D5648) 
with 10% fetal bovine serum (FBS), 100 I.U./ml penicillin, 100 μg/ml streptomycin, 
and incubated at 37°C in a humidified incubator with 5% CO2. C2C12 myoblasts 
were obtained from ATCC and cultured in DMEM with 10% FBS until confluent. 
After reaching confluency, the myoblasts were differentiated in DMEM with 2% 
horse serum and 1 µg/ml insulin for 72 hours, as previously described198. 
Resveratrol for in-vitro studies was purchased from Sigma-Aldrich (R5010) and 
stocks were diluted in DMSO. Ex-527 was purchased from Santa Cruz 
Biotechnology (CAS 49843-98-3). NBD peptide / NF-κB blocker (ALX-163-011-1) 
was purchased from Enzo Life Sciences. FoxO1 inhibitor, AS-1842856 (16761) 
and Nox4 inhibitor, GKT 137831 (1218942218942-37-0) was purchased from 
Cayman Chemical. BMX-001 was a kind gift from Dr. Rebecca Oberley-Deegan 
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(UNMC). Leucovorin, Oxaliplatin, 5-fluoroplatin, Irinotecan and Gemcitabine were 
purchased from Nebraska Medicine Pharmacy.  
Lentivirus and Adenovirus Transfection 
Cell transfections for producing replication-incompetent lentivirus were performed 
by utilizing Turbofect (Thermo Scientific), following the manufacturer's protocol. 
Stable short hairpin RNA (shRNA) constructs for Sirt1 were obtained from Sigma-
Aldrich. After transfection, cells were selected using puromycin. Human NOX4 
adenovirus was a kind gift from Dr. Melissa Teoh Fitzgerald (UNMC). GFP 
adenovirus was a kind gift from Dr. Matthew Zimmerman (UNMC). 
Mouse Sirt1 adenovirus was purchased from ABM (222151A). C2C12 myotubes 
were differentiated for 48 hours following which, a MOI (multiplicity of infection) of 
200 was used to transfect the myotubes.  
Cancer Cell-conditioned Media Preparation 
For conditioned medium (CM) preparation, S2-013 and T3M4 cell lines were 
seeded as previously described198. After attachment, cells were washed twice with 
1X phosphate buffered saline (PBS) and cultured in serum free DMEM for 24 
hours. The media was then collected and centrifuged at 3000 RPM for 10 minutes 
and the supernatant was collected in a fresh tube to be either used immediately or 





Cell Viability Assays 
Cell viability was determined by MTT assays as described previously198. All the 
MTT assays in this study were carried out at 72 hours post-treatment. 
RNA Isolation and qRT-PCR 
Total RNA was extracted from cells or tissue lysates by using TRIzol reagent 
(Invitrogen, Carlsbad, USA) as previously discussed201. Complementary DNA 
(cDNA) was synthesized using Verso-cDNA synthesis kit (Thermo fisher scientific, 
MA, USA) or High-Capacity Reverse Transcription Kit (Applied Biosystems) 
according to manufacturer’s protocol. qRT-PCR was performed using SYBR 
Green master mix (Applied Biosystems, NY, USA). Beta actin was used an internal 
control. Total RNA for RNA-seq analysis was isolated using RNAeasy columns 
(Qiagen) as per manufacturer’s protocol. Relative gene expression analysis were 
performed by utilizing ∆Ct method as described previously189. 
Chromatin immunoprecipitation assay 
Chromatin immunoprecipitation (ChIP) assay was performed as described 
previously189. Briefly, chromatin immunoprecipitation was performed by utilizing 
NFκB p65 along with IgG control. 3 µl purified chromatin for each reaction were 
used for qPCR analysis. The threshold cycle (Ct), values obtained for each 
genomic region were utilized for further analysis. For ChIP qPCR analysis, Ct 
values were normalized to an input control and represented as a fold increase over 





Immunohistochemistry was performed as described previously201 We utilized 
Novolink Polymer (Leica, Wetzlar, Germany), as per the manufacturer’s 
instructions. Muscle sections prepared from human patient tissues were stained 
with SIRT1 antibody (Cell Signaling Technology, Danvers, MA) and NOX4 
antibody (Abcam, Cambridge, UK). Each muscle fiber in a cross-sectional field of 
view was given an intensity score by evaluating staining intensity of positive 
staining (0 = none, 1 = weak, 2 = intermediate, 3 = strong). The histoscore was 
calculated by multiplying the percentage of fibers (0-100) with the particular score 
by its corresponding intensity score (0-3). All the scores in a given section were 
added, and the value was then divided by 100 to attain a score between 1 and 3. 
Immunoblotting 
Protein isolation and western blotting were performed as described previously [49]. 
Briefly, cells were washed twice with PBS and lysed in radio-immunoprecipitation 
assay (RIPA) lysis buffer by incubating at 4°C shaker for 10 min. Then, the lysates 
were centrifuged at 13000 rpm for 5 min and supernatant was collected. Protein 
concentration was measured by Bradford assay. Equal amounts of protein were 
used for western blotting. Primary antibodies against MuRF1, ATROGIN-1, p65 
(NF-κB) (Santa Cruz Biotechnology, Dallas, Texas, USA), Sirt1, FoxO3a, FoxO1, 
Acetyl-p65 (K310) (Cell Signaling Technology, Danvers, MA, USA), Tubulin and 
Myosin heavy chain 2 (Developmental Studies Hybridoma Bank, Iowa City, IA) , 
Nox4 ( Abcam) were utilized for probing specific proteins. 
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SIRT1 Activity Assay 
SIRT1 activity was measured in myotubes by using Sirt1 activity assay kit following 
manufacturer’s protocol (Sigma Aldrich CS1040). C2C12 myotubes were treated 
with either control media, S2-013- orT3M4- conditioned media for 24 hours and 
Sirt1 activity was measured. 
NF-κB Reporter Assay 
NF-κB luciferase adenovirus was purchased from Vector Biolabs (1740). C2C12 
cells were seeded and differentiated in 6-wells plates as previously mentioned. 
C2C12 myotubes were then treated with cancer-cell CM for 6 hours with and 
without resveratrol. After 6 hours, cells were harvested and assayed for luciferase 
activity using Promega Luciferase Reporter Assay according to manufacturer’s 
instructions (#E1690). 
Animal Studies 
Orthotopic Studies: All the animal experiments performed in this study were 
approved by University of Nebraska Medical Center Institutional Animal Care and 
Use Committee (IACUC). Athymic female nude mice (NCr-nu/nu) were bred in-
house and 6–8-week-old mice were used for orthotopic implantations. 0.5 × 106 
S2-013 scrambled control, S2-013 shSIRT1-A, or S2-013 shSIRT1-B cells were 
injected into the pancreas of female athymic nude mice and 7 days post-
implantation mice were segregated into groups of 10 animals each. Age and 
gender-matched mice, without any tumor cell injection, were utilized as healthy 
controls. Trans-resveratrol (Cayman Chemical, Ann Arbor, MI, Catalog #70675) 
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was solubilized in 1.5% methylcellulose with vigorous vortexing202. Beginning on 
day 7, mice received a daily oral treatment of 200mg/kg delivered using a 20G 
gavage needle. Tumor volumes and body weights were recorded regularly. After 
14 days of treatment, all the mice were euthanized and tumor weight, tumor 
volume, gastrocnemius muscle weight, and body weight were measured. Tumor 
tissue, liver, spleen, and muscles were flash frozen in liquid nitrogen and formalin 
fixed for further analysis 
For GKT studies, 0.25 X 106 S2-013 cells were implanted in the pancreas of 
athymic nude mice. The mice were randomly divided into two groups. GKT137831 
was solubilized in 1.2% of methylcellulose and 0.1% of polysorbate 80 and was 
administered to 10 tumor-bearing mice at a concentration of 60 mg/kg via daily 
oral gavage. The rest were administered the vehicle solution. To test for toxicity, 
we also injected 4 healthy mice with GKT137831. 
KPC tissues: The muscles of 10, 15 and 25 weeks of KrasLSL.G12D/+; p53R172H/+; 
Pdx1-Cretg/+ (KPC) mouse spontaneous progression model of pancreatic cancer 
were collected by euthanizing these mice along with littermate control.  
Transgenic Mice Model: C57BL/6 Mice having Tamoxifen-inducible muscle 
specific CRE was obtained from Jackson Laboratories (Tg(ACTA1-
cre/Esr1*)2Kesr/J ; Stock No. 025750 ). Mice having Nox4 floxed were a kind gift 
from Dr. Junichi Sadoshima (Rutgers). These mice were crossbred and genotyped 
to get the desired mice genotype (Nox4fl/fl: ACTA1-cre). Nox4 knockout was 
induced in the muscle by administration of Tamoxifen for 5 consecutive days at a 
concentration of 75 mg/kg as directed by Jackson laboratories. 
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0.25 X 105 KPC 1245 cells were implanted in the pancreas of male age-matched 
Nox4fl/fl: ACTA1-cre mice. Post-implantation, mice were segregated into two 
groups of 8 mice each and one group was injected with tamoxifen to induce Nox4 
deletion in the muscles. 
Chemotherapy studies on Mice: Male C57/BL6 mice were treated with 
FOLFIRINOX (100 mg/kg leucovorin, 5 mg/kg oxaliplatin, 50 mg/kg 5-fluorouracil, 
and 50 mg/kg irinotecan) once a week via tail vein injection. Mice were treated with 
gemcitabine at a concentration of 50 mg/kg twice a week via intraperitoneal 
injection (IP). BMX-001 was injected via IP at a concentration of 0.5 mg/kg. 
Mouse Body Fat Measurement 
Fat percent in each mouse was measured by Dual-energy X-ray absorptiometry 
(DEXA) scanning on the 18th day after implantation as previously mentioned203. 
Mice were anesthetized using a mixture of isoflurane and oxygen and placed on 
imaging positioning tray. Mice were scanned using a Lunar PIXImusTM 
densitometer (GE Medical-Lunar, Madison, WI). 
Measurement of Grip Strength 
A grip strength meter (Columbus Instruments, OH, USA) was utilized to assess 
forelimb grip strength as previously mentioned198. On the 18th day of treatment, we 
acclimatized mice to the procedure room for 15 minutes and measured grip 
strength as per manufacturer's instructions. We utilized the average value of three 





Skeletal muscle specimens were collected from pancreatic cancer patients under 
UNMC Rapid Autopsy Program (RAP).  
Detection of Reactive Oxygen Species in Muscles 
Electron paramagnetic resonance spectroscopy was utilized to detect oxygen 
radicals in the muscle tissues as previously described204. Briefly, gastrocnemius 
muscle tissues were harvested and incubated for 1 h at 37°C with the cell-
permeable O2˙−-sensitive spin probe 1-hydroxy-3-methoxycarbonyl-2,2,5,5-
tetramethylpyrrolidine (CMH, 200 μmol/l, Noxygen Science Transfer and 
Diagnostics, Elzach, Germany) in a Krebs-HEPES buffer (pH 7.4) containing (in 
mmol/l) 99 NaCl, 4.69 KCl, 2.5 CaCl2, 1.2 MgSO4, 25 NaHCO3, 1.03 KH2PO4, 5.6 
d-glucose, 20 HEPES, and supplemented with the metal chelators DETC (5 μM) 
and deferoxamine (25 μM). The EPR-CMH spectra was normalized to the 
gastrocnemius muscle weight. 
ROS Assay 
Reactive oxygen species in cells were determined as described previously205. ROS 
levels were determined by using oxidation-sensitive fluorescent dye 2′,7′–
dichlorofluorescin diacetate (DCFDA). C2C12 cells were seeded at 3.0 × 104 cells 
per well in a clear bottom black 96-well plate. The C2C12 myotubes were then 
differentiated and treated with the conditioned media for 8 hours. The media was 
replaced with fresh DMEM containing 20 μM DCFDA. H2O2 along with DCFDA was 
used as a positive control and 2′,7′-Bis(2-carboxyethyl)-5(6)-carboxyfluorescein 
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was used as a negative control. Control, and treated cells were incubated at 37°C 
for 30 min. The cells were washed with PBS and 100 μL of PBS was added to the 
wells for measuring the emission of DCFDA using a Biotek Cytation 3 plate reader 
(BioTek Instruments Inc, Winooski, Vermont). DCFDA fluorescence was 
measured at 485 nm excitation wavelength and 529 nm emission wavelength. 
Glucose Uptake Assay 
Glucose uptake assay was performed as previously described205. Briefly, S2-013 
and T3M4 cells were seeded at a density of 5 x 104 cells/well in 12-well plates. 
After overnight attachment, the cells were treated with resveratrol (25 µM) or Ex-
527 (0.5 µM) for 24 hours. The cells were then starved for 2 hours in DMEM without 
glucose, glutamine, pyruvate, and fetal bovine serum. [3H]2-deoxy glucose was 
then added to the wells, incubated for 20 minutes, washed once with 1X PBS and 
then lysed with 1% SDS (sodium dodecyl sulfate). The lysates were then counted 
for tritium incorporation by a scintillation counter, which was then normalized 
according to cell counts. For C2C12 myotubes, glucose uptake was performed 
after the differentiated myotubes were treated for 24 hours and normalization was 
done using protein content.  
RNA-seq Analysis 
RNA sequencing was performed on myotubes treated with S2-013 CM with and 
without resveratrol. All gene sets in GMT format with Entrez IDs for Mus musculus 
were downloaded from http://ge-lab.org/gskb/. The gene set for TFactS 
(http://www.tfacts.org/) was chosen from the list and was made into a separate file, 
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converted into gene symbols through ensembl biomart 
(https://www.ensembl.org/biomart), and predicted genes and pseudogene were 
removed (n=10) before being used by GSEA2 v2.2.3 with 1000 permutations in 
the classic scoring scheme. Heatmap of the normalized enrichment score was 
produced in R v3.3.2 with the gplots package after filtering for the top 25% percent 
most variable gene sets. 
Patient Data  
Our retrospective cohort study included all pancreatic cancer patients between 
2009 and 2017 at University of Nebraska Medical Center, Omaha, Nebraska, USA 
who were recipients of chemotherapy and underwent an abdominal CT scan at the 
time of diagnosis and an interval scan at 8 weeks following chemotherapy. Prior to 
exclusion, we had 1280 patients with a diagnosis of pancreatic cancer at our 
institution. Exclusions included those who were treated at other institutions, those 
who did not have a follow-up CT scan and those who did not receive 
chemotherapy. After exclusion, we were left with a total of 162 patients.   
The study was approved by the UNMC institutional review board. The UNMC 
electronic data source, including patients electronic medical record (EMR), and the 
cancer registry provided information on height, weight, disease stage, tumor 
characteristics, demographics and cancer treatment including surgery type (no 
surgery, pancreaticoduodenectomy or distal pancreatectomy) and the receipt of 
chemotherapy and/or radiation. Height and weight were measured at a clinical visit 




Body composition/CT image analysis of muscle mass  
Abdominal CT scans at cancer diagnosis (prior to therapy initiation) and at 2-month 
follow-up after treatment was retrieved from the picture archiving and 
communication system (PACS) in our institution. Slice-O-Matic software version 
5.0 (Tomovision) was used to calculate muscle mass by selecting a single CT slice 
at the level of the third lumbar vertebrae (L3). Muscle mass was identified using 
the Hounsfield unit threshold of −29 to +150 and measured as cross-section 


















Chapter 3: Role of Sirtuin 1 in Pancreatic Cancer 
Cachexia 
(Note – The data shown in this chapter has been submitted to a peer-reviewed journal 
as of March 2019) 
 
Introduction 
Pancreatic cancer is the third leading cause of cancer-related deaths in the United 
States206. It is predicted that by the year 2030, it will be the second leading cause 
of cancer-related deaths207. The dismal five-year survival rate of pancreatic cancer 
patients can be attributed to a variety of factors, including late diagnosis, early 
metastasis, resistance to chemotherapy, and cachexia. Cachexia is a metabolic 
syndrome that is observed in up to 80% of pancreatic cancer patients208. One-third 
of pancreatic cancer patients die due to cachexia-associated complications, 
entailing respiratory or cardiac failure209. In pancreatic cancer patients, cachexia is 
associated with poor response to chemotherapy and decreased overall 
survival5,210. 
Cachexia is defined as the loss in skeletal muscle mass that cannot be fully 
reversed by conventional nutritional therapy and leads to progressive functional 
impairment3. Until now, the manifestation of cancer cachexia has been attributed 
to systemic inflammation caused by the host body and tumor-derived 
cytokines208,211. Multiple clinical trials for combating cachexia with anti-
inflammatory agents have demonstrated unsatisfactory results212. Currently there 
are no FDA approved drugs to mitigate cancer-induced cachexia. Thus, there is 
an urgent need to find more efficient therapeutic targets. 
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Sirtuins are primarily NAD+-dependent protein deacetylases and mono- 
[ADP-ribosyl] transferases213. They can sense energy fluctuations in the cells as 
their enzymatic activity is dependent on using NAD+ as a cofactor. There are seven 
mammalian sirtuins and they are also referred to as class III histone 
deacetylases214. The cellular localization of the sirtuins varies. Some sirtuins are 
present in the cytoplasm or the nucleus and the others in the mitochondria. 
Mammalian sirtuins are involved in various functions such as chromatin regulation, 
metabolic homeostasis, and cell survival under stress214.   
It is now well-established that increased expression of muscle specific 
ubiquitin ligases (MuRF1 and MAFbx/Atrogin) are a hallmark of muscle 
atrophy215,216. These genes are activated by the FoxO family of transcription 
factors217,218. Activities of FoxO1 and FoxO3 are regulated by cycles of acetylation 
and deacetylation; the latter being mediated by a sirtuin family member SIRT1219.  
The role of SIRT1 in cancer is very ambiguous. It could act either as a tumor 
suppressor or a tumor promoter, depending on its cellular context, and may have 
different signaling targets in different cancer types220,221. In pancreatic cancer, 
SIRT1-activating compounds (STACs) decrease tumor growth in vivo and in vitro 
through a lysosome dependent pathway222. Sirtuins have also been illustrated to 
play a role in muscle health223-225. To the best of our knowledge, the role of sirtuins 
in pancreatic cancer cachexia has not yet been evaluated. 
In this chapter, we elucidated the potential utility of targeting sirtuins in 
combating pancreatic cancer cachexia. Moreover, we investigated whether 
inhibition or activation of sirtuins in the muscle, irrespective of its effect in the tumor, 
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would be sufficient to combat muscle wasting. Our findings demonstrate that 





















Expression of sirtuins in cachectic muscles 
We evaluated the sirtuins that are altered in the pancreatic cancer-induced 
cachectic muscle by determining the mRNA expression levels of all the seven 
sirtuins in the gastrocnemius muscles from 10, 15, and 25-weeks-old KPC 
spontaneous PDAC mice model and comparing them to the littermate controls.  
Sirt1 expression was significantly decreased in gastrocnemius muscles from KPC 
mice at 15 and 25 weeks of age, compared to that from the littermate controls 
(Figure 7). However, we observed no significant alterations in the other sirtuins, 
except for Sirt2, which was decreased in the KPC mice muscles only at 25-weeks 















Figure 7 : Sirt1 expression in KPC muscles.  Sirt1 mRNA expression in KPC 
mice gastrocnemius muscles (n=3) at 10, 15, and 25 weeks post birth. Data are 









Figure 8 : Expression of all sirtuins in KPC muscles.  Sirtuin mRNA expression 
in gastrocnemius muscles from KPC mice at 10, 15, and 25 weeks of age. Data 







We also wanted to evaluate if cachectic cancer patients had a similar decrease in 
SIRT1 expression in skeletal muscles. For this purpose, we utilized muscle 
sections from pancreatic cancer patients obtained from the Rapid Autopsy 
Program at the University of Nebraska Medical Center. We observed decreased 
muscle fiber cross-sectional area, along with a decrease in SIRT1 staining in 
pancreatic cancer patient skeletal muscle sections (Figure 9A). We scored 54 
patient muscle samples and observed a significant positive correlation between 
muscle cross-section area and SIRT1 staining (Figure 9B, Table 2). We 
investigated whether this phenotype was evident in other models of cancer 
cachexia. We observed that muscles collected from C-26 colon tumor-bearing 
mice also demonstrated a decrease in Sirt1 expression, with no significant 






















Figure 9 : Expression of SIRT1 in pancreatic cancer patients’ muscles. (A) 
IHC staining of Sirt1 in skeletal muscles of pancreatic cancer patients were scored 
according to the staining intensity. (B) Correlation of the average skeletal muscle 
fiber cross-section area with the SIRT1 histoscore in 54 muscle autopsy samples 
of pancreatic cancer patients. ‘R’ depicts Pearson’s correlation coefficient and p 





























Table 2 : Patient characteristics for samples used for SIRT1 and Nox4 staining. 
  Number Frequency 
    
Age 40-49 2 3.7 
 50-59 9 16.7 
 60-69 25 46.3 











Stage I 2 3.7 
 IIA/B 9 16.7 







    
Gender F 15 27.8 
 M 39 72.2 
    
Radiotherapy No 30 55.6 
 Yes 19 35.2 















    
Chemotherapy None 3 5.6 
 FOLFIRINOX 3 5.6 
 Gemcitabine 17 31.5 





















Figure 10 : Expression of Sirtuins in the C-26 model.  Sirtuin mRNA expression 
in gastrocnemius muscles from C26 tumor-bearing mice at day 21 post 






In order to evaluate whether cancer cell-secreted factors could diminish Sirt1 
expression in myotubes, we utilized the in vitro model of pancreatic cancer-induced 
muscle atrophy. We treated C2C12 myotubes with CM from human (S2-013 and 
T3M4) and mice (KPC 1245, 1199, and 242) pancreatic cancer cell lines. We 
observed that the mRNA levels of Sirt1 decreased in C2C12 myotubes upon 
treatment with human and mice PDAC cell line-CM (Figure 11A). We also 
observed that expression of other sirtuins were not consistently altered (Figure 
11B). Moreover, we also confirmed that the decreased expression correlated with 
decreased Sirt1 activity in the C2C12 myotubes upon treatment with cancer cell-


























Figure 11 : Expression of sirtuins in CM-induced muscle atrophy.  (A) Sirt1 
mRNA expression in myotubes treated with S2-013-, T3M4-, KPC 1245-, KPC 
1199-, and KPC 242-conditioned media, (B) Sirt2-7 mRNA expression in myotubes 
treated with S2-013-, T3M4-, KPC 1245-, KPC 1199- and KPC 242-CM for 24 
hours. Data are mean ± S.E.M., compared with one-way ANOVA with Dunnett’s 
multiple comparisons. p*<0.05; p**<0.01; p***<0.001. (C) Sirt1 activity in myotubes 
treated with S2-013- and T3M4-CM for 24 hours. Data are mean ± S.E.M., 











































































































































































































































































































































































Since we observed a decrease in Sirt1, we hypothesized that stabilization of this 
protein might lead to rescue of cancer induced muscle atrophy. Previous studies 
have established that resveratrol (3,5,4’-trihydroxystilbene), a natural phytoalexin 
and a polyphenol found in red wine increases the deacetylase activity of SIRT1226. 
It has also been shown to increase the expression of SIRT1227-229. Since we 
observed that Sirt1 levels were decreased in cachectic muscles, we next 
investigated the effect of resveratrol on the cachectic phenotype. Treatment with 
cancer cell-CM and resveratrol (50 µM) rescued C2C12 myotube degeneration in 
culture conditions, as measured by myotube thickness (Figure 12A, 12B). There 
was also rescue of the cancer cell-CM-induced decrease in myosin heavy chain 
expression. Resveratrol also diminished the cancer cell-CM-induced protein 
expression of Atrogin-1 and MuRF1 muscle-specific ubiquitin ligases, which 
mediate muscle breakdown (Figure 12C). The mRNA levels of MuRF1 (Trim63) 
and Atrogin-1 (Fbxo32) were also decreased upon addition of resveratrol to the 
CM (Figure 13). We also observed resveratrol-mediated rescue of Sirt1 mRNA 
levels in the myotubes upon treatment with conditioned-medium (Figure 13). It is 
important to mention that resveratrol did not alter the expression of other sirtuins 



















Figure 12 : Resveratrol rescues CM-induced atrophy in C2C12 myotubes.  (A) 
Brightfield microscopy images (at 200x) of myotubes treated with S2-013-CM and 
T3M4-CM with and without resveratrol (50 µM) treatment for 24 hours. Scale bars 
represent 50 µm. (B) Myotube width was measured by ImageJ. Five 
measurements were taken along the length of each myotube. (C) Immunoblots of 
MyHC, Atrogin-1, and MuRF-1 in myotubes treated with S2-013- and T3M4-CM 
along with resveratrol treatment for 24 hrs. Tubulin was used as a loading control. 























































Figure 13 : Resveratrol decreases CM-induced increase in atrophy genes. 
mRNA expression of Trim63 (MuRF-1), FBXO32 (Atrogin-1) and Sirt1 in myotubes 
treated with S2-013- and T3M4-CM along with resveratrol (50 µM) for 24 hrs. Data 




SIRT1 activation in pancreatic cancer cell lines leads to a decrease in 
proliferation 
Next, we wanted to investigate the efficacy of systemic modulation of Sirt1 in 
diminishing muscle atrophy in mice. It was important to first evaluate the effect of 
resveratrol on pancreatic cancer cell lines, so that we could delineate its effect on 
muscles independent of its effect on tumor. Previous studies have demonstrated 
that resveratrol decreases proliferation of some pancreatic cancer cells230-232. We 
wanted to determine if treatment of pancreatic cancer cell lines with resveratrol 
would impact cell proliferation in our cell line models. Therefore, we treated S2-
013 and T3M4 cells with multiple doses of resveratrol.  We observed that treatment 
with resveratrol decreased cell proliferation in a dose-dependent manner (Figure 
14A). Moreover, since pancreatic tumors have high rates of glycolysis233, we also 
evaluated whether resveratrol modified the glycolytic phenotype of pancreatic 
cancer cells. We observed that resveratrol decreased glucose uptake in pancreatic 
cancer cell lines (Figure 14B). We also observed that Ex-527, a SIRT1 inhibitor 
that has previously been shown to increase tumor growth rates in vivo234, 
increased glucose uptake in S2-013 and T3M4 PDAC cell lines (Figure 14C). 
Resveratrol treatment also increased glucose uptake in myotubes treated with 
cancer cell-CM (Figure 14D). These results demonstrated that resveratrol had an 
adverse effect on tumor growth, but it also rescued glucose uptake in myotubes 
















Figure 14 : Effect of resveratrol on pancreatic cancer cells. (A) MTT assay 
demonstrating the dose-dependent effect of resveratrol on S2-013 and T3M4 cell 
survival 72 hours post treatment. (B) Relative glucose uptake in S2-013 and T3M4 
cells upon resveratrol treatment (50 µM) for 24 hrs. (C) Glucose uptake in S2-013 
and T3M4 cells upon Ex-527 (0.5 µM) treatment for 24 hrs. (D) Glucose uptake in 
C2C12 myotubes upon treatment with cancer cell-conditioned media (CM) and 
resveratrol for 24 hrs. Data are mean ± S.E.M., One-way ANOVA with Dunnett’s 







To develop a model to test the effect of resveratrol on the muscle, independent of 
its effect on the tumor, we generated SIRT1 knockdowns in S2-013 cells by 
lentiviral-delivery of short hairpin RNA (shRNA) against SIRT1. Two constructs 
targeting independent regions of SIRT1, shSIRT1-A and shSIRT1-B were used for 
knocking down SIRT1 expression (Figure 15A). We then investigated whether 
SIRT1 knockdown altered the sensitivity of cancer cells to resveratrol (25 µM) by 
performing MTT assays. We observed that SIRT1 knockdown cells were less 
sensitive to resveratrol (Figure 15B). Moreover, cancer cell-CM from the scrambled 
control and the SIRT1 knockdown cell lines had similar effect on the protein 
content of the myotubes, implying that modulation of SIRT1 in the tumor has no 



























Figure 15 : Effect of Resveratrol on Sirt1 knockdown pancreatic cancer cells 
lines.  (A) Immunoblot of SIRT1 in S2-013 cells. Tubulin was used as a loading 
control. (B) Relative survival of S2-013 shScr, shSIRT1-A and shSIRT1-B upon 
resveratrol treatment for 72 hours (25µM) by MTT assays. (C) Protein content in 
myotubes treated with S2-013 shScr-CM, S2-013 shSIRT1-A-CM, S2-013 
shSIRT1-B-CM along with resveratrol (50 µM). Data are mean ± S.E.M., Two-way 
ANOVA with Bonferroni’s post-hoc analysis considering the interaction between 
treatment and cell line (B), One-way ANOVA with Bonferroni’s multiple 






Resveratrol prevents pancreatic cancer-induced cachexia in vivo 
independent of its effect on the tumor. 
To extrapolate our findings, we evaluated whether stabilizing the expression of 
Sirt1 in skeletal muscles by resveratrol would rescue muscle atrophy in animal 
models. We implanted scrambled control and SIRT1 knockdown S2-013 cells 
orthotopically into the pancreas of athymic nude mice and administered resveratrol 
(200 mg/kg) daily by oral gavage, starting at 6 days post-implantation (Figure 16A). 
We observed decreased tumor weight and volume upon necropsy in resveratrol-
treated scrambled control tumor-bearing mice but not in the SIRT1 knockdown 
cells (Figure 16B, C). We also observed that resveratrol significantly diminished 

















Figure 16 : Resveratrol decreases growth of Sirt1 wildtype but not Sirt1 KD 
tumors  (A) Schematic illustration of the treatment strategy. (B-C) Post necropsy 
measurements of S2-013 shScr (n=10), shSIRT1-A (n=10), and shSIRT1-B (n=10) 
tumor weights (B) and tumor volumes (C). Data are mean ± S.E.M., One-way 







Additionally, post-necropsy measurements demonstrated a significant rescue in 
gastrocnemius muscle weight upon resveratrol treatment (Figure 17B). We 
measured body fat percentage by performing DEXA scans at day 18 post-
implantation and observed a significant increase in body fat percentage in tumor-
bearing mice upon resveratrol treatment (Figure 17C). There was also a significant 
improvement in the forelimb grip strength of the mice cohorts treated with 
resveratrol (Figure 17D). Quantification of the gastrocnemius muscle fiber cross-
sectional area in hematoxylin and eosin-stained tissue sections showed significant 
increase in the mice treated with resveratrol (Figure 17E). There was an increased 
expression of myosin heavy chain and decreased expression of MuRF1 and 
Atrogin-1 in the gastrocnemius muscles of the mice treated with resveratrol (Figure 
17F). Importantly, SIRT1 immunoblotting and IHC staining of gastrocnemius 
muscle sections confirmed SIRT1 stabilization upon treatment with resveratrol 















Figure 17 : Resveratrol rescues muscle wasting in tumor-bearing mice. (A) 
Change in body weight measurements of the tumor-bearing mice on day 21 post 
implantation. (B) Post necropsy gastrocnemius muscle weight from S2-013 shScr, 
S2-013 shSIRT1-A and S2-013 shSIRT1-B tumor-bearing mice. (C) Measurement 
of fat percentage of S2-013 shScr (n=8), S2-013 shSIRT1-A (n=8) and S2-013 
shSIRT1-B (n=8) tumor-bearing mice by DEXA scanning on day 18th post 
implantation. (D) Measurement of grip strength of the tumor-bearing mice on day 
18th post implantation. (E) Quantification of muscle fiber cross-sectional area in 
hematoxylin and eosin-stained muscle sections from the tumor-bearing mice. (F) 
Immunoblots of muscle tissue extracts from the tumor-bearing mice showing 
regulation of MyHC, Atrogin, MuRF1, FoxO1, and FoxO3. Tubulin was used as a 
loading control. Data are mean ± S.E.M., One-way ANOVA with Bonferroni’s 





















Figure 18 : Resveratrol stabilizes SIRT1 in the gastrocnemius muscles of 
tumor-bearing mice. SIRT1 staining in gastrocnemius muscles of healthy 
controls and tumor-bearing mice treated with vehicle control or resveratrol. 



















Resveratrol prevents muscle wasting by reducing ROS levels, and 
diminishing the expression and activity of FOXO transcription factors 
In order to investigate the potential mechanism of action of resveratrol-induced 
protection against muscle wasting, we performed RNA-seq analysis on myotubes 
treated with S2-013-CM with or without resveratrol for 24 hours. Since Sirt1 is 
known to be involved in regulation of several transcription factors, we performed 
Gene Set Enrichment Analysis (GSEA) and determined the enrichment for 
transcription factors in the transcription factor gene set from TFactS 
(http://www.tfacts.org/) to evaluate the significantly altered pathways in all the 
cohorts (Figure 19A). We observed significant alterations in 9 out of 101 
transcription factor pathways (Figure 19B). Interestingly, we observed enrichment 
of FoxO1 and FoxO3 transcription factor-regulated genes in the myotubes treated 
with S2-013-CM (Figure 19C). These set of genes also include Fbxo32 (Atrogin) 
and Trim63 (MuRF-1) which are muscle-specific ubiquitin ligases65,66 responsible 
for muscle atrophy. These enrichments were abolished by resveratrol treatment. 
We validated the RNA-Seq results by evaluating the mRNA and protein levels of 
FoxO1 and FoxO3 in myotubes treated with cancer cell-CM with or without 
resveratrol. We observed that resveratrol decreased the cancer cell CM-induced 
expression of the FoxO genes (Figure 19D). Similar results were observed in the 
protein levels of FoxO1 and FoxO3 (Figure 19E), confirming that resveratrol 











Figure 19 : Resveratrol reverts cancer cell-CM-induced upregulation of FoxO 
proteins via NF-κB.  (A) Schematic illustration of the flow chart of RNA-Seq 
analysis. (B) Heatmap showing the Z-score changes in the 3 comparisons. 9 out 
of 101 pathways in the transcription factor database from TFactS were significantly 
altered. (C) GSEA plots of FoxO1 and FoxO3. The normalized enrichment scores 
(NES) for FoxO1 are 2.07 (CM-treated vs. control) and -1.9 (CM+Res-treated vs. 
CM-treated) pathway. The NES for FoxO3 are 2.5 (CM-treated vs. control) and 1.6 
(CM+Res-treated vs. CM-treated). (D) mRNA levels of Foxo1 and Foxo3 in 
myotubes upon treatment with tumor cell-CM and resveratrol (50 µM). Data are 
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Next, we evaluated the potential direct relationship between Sirt1 expression and 
muscle pathophysiology. For this purpose, we overexpressed Sirt1 by adenoviral 
infection of myotubes after 48 hours of differentiation, and then treated them with 
cancer cell-CM for 24 hours. Sirt1 overexpression attenuated the thinning of 
myotubes induced by cancer cell-CM (Figure 20A). Consequently, Sirt1 
overexpression also rescued the loss of protein content in myotubes upon CM 
treatment (Figure 20B). Sirt1 overexpression also rescued the cancer CM-induced 
decrease in myosin heavy chain expression levels. (Figure 20C). We also 
observed a decrease in the mRNA levels of the FoxO1 and FoxO3 upon Sirt1 
overexpression in CM-treated myotubes (Figure 21). Therefore, we concluded that 











Figure 20 : SIRT1 overexpression rescues atrophy in C2C12 myotubes. (A) 
Brightfield microscopy images (at 200x), protein content analysis (B), protein lysate 
immunoblot analysis (C) of GFP control or SIRT1 expressing myotubes, infected 
adenovirally (Ad), upon treatment with tumor cell-CM for 24 hours. Scale bars 
represent 75µm. Data are mean ± S.E.M., One-way ANOVA with Bonferroni’s 

























Figure 21 : SIRT1 regulates expression of FOXO proteins in C2C12 
myotubes. Foxo1 and Foxo3 mRNA analysis (A) of GFP control or SIRT1 
expressing myotubes, infected adenovirally (Ad), upon treatment with tumor cell-
CM for 24 hours. Data are mean ± S.E.M., One-way ANOVA with Bonferroni’s 















Additionally, the NF-B pathway, which has been shown to be a major player in 
the development of cachexia235, was also significantly upregulated in myotubes 
treated with S2-013-CM, and this increase too was abrogated by resveratrol 
treatment (Figure 22A). These results are in line with previous studies 
demonstrating the regulation of NF-κB activity by Sirt1-mediated deacetylation236-
238. Moreover, a promoter-reporter assay with an NF-κB-responsive promoter-
luciferase reporter construct showed that resveratrol abolished the cancer cell-CM 
induced NF-κB transcriptional activity in myotubes (Figure 22B). Previous studies 
have demonstrated increased transcription activity of NF-κB upon acetylation of 
p65 at lysine 310239. Since K310 residue of p65 has been known to be deacetylated 
by SIRT1240, we evaluated K310 acetylation levels upon treatment of myotubes 
with cancer cell-CM with and without resveratrol. We observed increased 
acetylation of p65 upon cancer-cell CM treatment, and the effect was reduced by 
resveratrol treatment (Figure 22C). In the next chapter, we will illustrate the 




















Figure 22: Resveratrol rescues tumor-induced increase in NF-κB pathway.  
(A) GSEA plots for NF-κB. NES for NF-κB are 2.91 (CM-treated vs. control) and 
1.6 (CM+Res-treated vs. CM-treated). (B) Luciferase assay to measure NF-κB-
responsive promoter-luciferase reporter activity upon treatment of myotubes with 
cancer cell-CM with and without resveratrol (50 µM) for 6 hours. (C) Immunoblot 
analysis of acetylated (taken at high and low exposures) and total p65 subunit of 
NF-κB in myotubes treated with cancer cell-CM with and without resveratrol (50 
µM) for 24 hours. Data are mean ± S.E.M., One-way ANOVA with Bonferroni’s 












In our study, we concluded that SIRT1 stabilization in the muscles successfully 
prevented muscle atrophy induced by pancreatic tumors in orthotopic mouse 
models. Additionally, the loss of SIRT1 in skeletal muscles was consistent across 
spontaneous progression models and human cancer patients. While, we did not 
observe a consistent alteration in the expression levels of other sirtuins in the 
cachectic muscles, we cannot rule out the roles played by other sirtuins in the 
tumor cells. Multiple sirtuins have been shown to regulate aggressiveness in tumor 
cells251,252 that may indirectly impart cachectic functions. Nonetheless, our studies 
establish that stabilizing/increasing SIRT1 expression may provide therapeutic 
opportunities for cancer cachexia. 
Previous studies have demonstrated that resveratrol decreases tumor 
growth in multiple myeloma, cervix carcinoma, and chronic myeloid leukemia253-
255. While we observed similar anti-cancer response on pancreatic cancer cell lines 
in culture and in orthotopic tumor models, we noted a direct effect of resveratrol-
mediated Sirt1 stabilization on preventing tumor-induced wasting in cultured 
myotubes and in mice muscles. Additionally, we demonstrated that resveratrol can 
abolish tumor-induced wasting in orthotopic models irrespective of its effects on 
the tumor and has the potential to be utilized as a therapy for cachexia.  
In our studies with the in-vitro models of cancer cell-CM-induced 
myodegeneration, RNA-Seq analysis demonstrated NF-κB to be the most altered 
pathway. This was in line with classical studies in cachexia that demonstrated NF-
κB to be the master regulator of ubiquitin proteasome in cancer-induced muscle 
86 
 
atrophy235,256. Even though previous studies have demonstrated an association of 
NF-κB activation and the proteins in the ubiquitin proteasome pathway256,257, a 
direct mechanism was still not known. We also observed tumor cell-induced 
expression of FoxO proteins, which are known to be regulated by oxidative and 
metabolic stress258. Based on the previous evidence highlighting the anti-oxidant 
functions of resveratrol238 and the influence of oxidative stress on muscle 
wasting259,260, we next asked if the decrease in muscle atrophy was due to altered 
redox signaling via NF-κB activation. We observed that direct inhibition of NF-κB 
was able to abolish the tumor cell-CM-induced expression of MuRF1 and Atrogin-
1 ubiquitin ligases that impart muscle wasting. Furthermore, we demonstrate that 
resveratrol can inhibit tumor cell-CM-induced activation of NF-κB. Hence, we 
establish that SIRT1 is an upstream regulator whose loss results in activation of 





Chapter 4 : Role of Nox4 in Cancer-Induced Cachexia 
 
(Note – The data shown in this chapter has been submitted to a peer-reviewed journal 
as of March 2019) 
 
Introduction 
Reactive Oxygen Species (ROS) are highly unstable, reactive and short-lived 
molecules which regulate signaling pathways in all cells, including skeletal muscle 
cells241. The major types of reactive oxygen species found in cells are superoxide, 
hydrogen peroxide and hydroxyl radical.  At high concentrations, free radicals can 
damage macromolecules and organelles, which thereby leads to tissue 
degeneration or dysfunction84. Studies have established the role of high oxidative 
stress or oxidative damage in the development of cancer-associated muscle 
wasting and the rescue of such wasting when treated with antioxidants86. Similarly, 
reports have also demonstrated induction of the ubiquitin proteasome pathway by 
mild oxidative stress242. In this chapter, we investigated the role of oxidative stress 
in the manifestation of pancreatic cancer cachexia. We evaluated the major 
enzymes involved in ROS homeostasis and observed the key role of NADPH 
oxidase 4 (Nox4) in the manifestation of cancer-cachexia. Nox enymes catalyze 
the formation of free radicals by transferring an electron from NADPH to oxygen. 
The mammalian Nox enzymes are Nox1 to Nox5, and Duox1 and Duox2243(Figure 
23). Among them, Nox4 is the only one which is constitutively active, with others 
being activated by calcium or protein-protein interactions. This feature of Nox4 also 
implies the relevance of evaluating the expression of Nox4 as compared to its 
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activity, presumption being that any protein that is expressed is constitutively 
active243. This chapter will illustrate the role of Nox4 in cachectic skeletal muscles 
and its potential of being a therapeutic target. This chapter will also link the findings 

















Figure 23 : Types of NADPH oxidases. “Nox family NADPH oxidases: 










Resveratrol reduces ROS levels in cachectic muscles 
Considering the established link between oxidative stress and muscle damage, 
continuing with the data presented in chapter 3, we wanted to evaluate whether 
reactive oxygen species (ROS) play a role downstream of Sirt1. On our advantage, 
previous studies have established an inverse relationship between SIRT1 and 
ROS levels in neuronal cells244. Hence, we investigated whether diminished SIRT1 
levels in cachectic muscles contributed to oxidative damage, resulting in muscle 
atrophy. We first tested our hypothesis in our in vitro model of cancer-induced 
muscle atrophy. Interestingly, we observed increased ROS levels in the myotubes 




















Figure 24 : Resveratrol decreases the tumor-induced ROS in C2C12 
myotubes. ROS levels in C2C12 myotubes after treatment with cancer cell-CM 
with or without resveratrol for 8 hours. Data are mean ± S.E.M., One-way ANOVA 













We next hypothesized that since ROS is increased in cachectic myotubes, there 
would be an induction or reduction in the enzymes involved in ROS homeostasis. 
To that end, we evaluated the levels of the key enzymes responsible for reactive 
oxygen homeostasis in the muscles of the tumor-bearing mice treated with 
resveratrol (Figure 25A, 25B and 26). Interestingly, we observed that mRNA levels 
of NADPH oxidase 4 (Nox4) were increased in the muscles of the tumor-bearing 
mice but downregulated upon treatment of the tumor-bearing mice with resveratrol, 



























Figure 25: Expression of ROS enzymes in the muscles of tumor-bearing 
mice.  (A)The mRNA levels of Nox4 in the gastrocnemius muscles from tumor cell-
implanted mice (n=3 for each group) with and without resveratrol treatment. (B) 
The mRNA levels of redox regulators in gastrocnemius muscles of tumor-bearing 
mice with and without resveratrol treatment (n=3 for each group); Nox1-3 (NADPH 
oxidase1-3), Sod1-2 (Superoxide Dismutase1-3). Data are mean ± S.E.M., 


























Figure 26 : Expression of ROS enzymes in gastrocnemius muscles in tumor-
bearing mice. The mRNA levels of redox regulators in gastrocnemius muscles of 
tumor-bearing mice with and without resveratrol treatment (n=3 for each group); 
Sod 3 (Superoxide Dismutase 3), Gpx1-4 (Glutathione peroxidase1-4), Catalase, 
Trdxn1-3 (Thioredoxin1-3). Data are mean ± S.E.M., compared with one-way 







Keeping in mind our results from Chapter 3, that Sirt1 regulates NF-κB and FoxO, 
we wanted to elucidate whether there was a redox link between the induction of 
NF-κB and Nox4. Intrigingly, previous reports have demonstrated the regulation of 
Nox4 by NF-κB245,246 in other models. To establish the direct regulation of Nox4 by 
NF-κB in cachectic skeletal muscles, we performed ChIP assays. The ChIP assays 
demonstrated increased occupancy of NF-κB (p65 subunit) at two consensus NF-
κB response elements in the promoter region of Nox4 in C2C12 myotubes upon 
treatment with S2-013- and T3M4-CM. Moreover, the increased Nox4 promoter 
occupancy of NF-κB in response to CM treatment was abrogated upon treatment 
with resveratrol (Figure 27A). These results indicate that CM treatment facilitates 
NF-κB activation and binding to Nox4 promoter, likely inducing the Nox4 
expression; these events can be abolished by resveratrol treatment. To prove this 
link via an independent method, we also utilized a cell permeable NF‐κB essential 
modulator (NEMO)‐binding domain (NBD) peptide that can block the activation of 
the IκB kinase (IKK) complex to inhibit NF-κB activity247. We observed abrogation 
of the cancer cell-CM-induced expression of Nox4 and myotube atrophy by treating 
the myotubes with NBD (Figure 27B and 27C). These results establish that in 













      





Figure 27 : NF-κB regulates the expression of Nox4 in cachectic muscles. . 
(A). ChIP analyses demonstrating distal (-1047) and proximal (-369) Nox4 
promoter region occupancy by NF-κB. (B-C) Nox4, Trim63 and Fbxo32 mRNA 
levels in C2C12 myotubes treated with cancer cell-CM and NBD. Data are mean 
± S.E.M., One-way ANOVA with Bonferroni’s multiple comparisons. p*<0.05; 









To validate our findings further, we wanted to evaluate the mRNA levels of Nox4 
in the muscles from 10-, 15-, and 25-week-old KPC mice. We observed a 
significant increase in Nox4 levels in the muscles of 25-week-old KPC mice (Figure 
28A). Moreover, overexpression of NOX4 in C2C12 myotubes via adenovirus 
infection directly led to myotube atrophy at 48 hours post-infection (Figure 28B), 
implying a causative link between Nox4 expression and myotube atrophy. NOX4 
overexpression also decreased the levels of myosin heavy chain in the myotubes 
(Figure 28C). Additionally, we also observed that overexpression of NOX4 was 
sufficient to increase the expression of FoxO genes (Figure 28D). These results 

























Figure 28 : Nox4 induces atrophy in cachectic muscles. (A) Nox4 mRNA levels 
in KPC mice muscles at 10-,15- and 25-weeks of age (n=3). (B) Brightfield 
microscopy images (at 200x) demonstrating thinning of C2C12 myotubes upon 
Nox4 overexpression. Scale bars represent 250µm. (C) Immunoblot analysis of 
Nox4 overexpressing myotube extracts depicting decrease in the levels of myosin 
heavy chain. Tubulin was used as a loading control. (D) Foxo1 and Foxo3 mRNA 
levels in C2C12 myotubes upon Nox4 overexpression for 48 hours. Data are mean 






Validating our findings in another model of cancer cachexia we found that muscles 
from C26-bearing mice also demonstrated an increase in Nox4 and FoxO genes, 
along with the induction of atrophy genes (Figure 29A,B). These results establish 
the critical role of Nox4 in induction of the cachectic phenotype. We then wanted 
to come back to our original premise that decreased Sirt1 led to Nox4 induction. 
Consequently, overexpression of Sirt1 was sufficient in downregulating the 
increased levels of Nox4 in the myotubes treated with cancer cell-CM (Figure 29C). 
These results led us to hypothesize that Sirt1 downregulation leads to NF-κB 
activation, which can lead to increased expression of Nox4, an inducer of oxidative 
stress that can in turn induce the expression of the muscle-specific ubiquitin 























Figure 29 : Expression of atrophy genes in the muscles of C26-bearing mice. 
(A-B) mRNA levels of Nox4, Foxo1, Foxo3, Trim63, and Fbxo32 in the 
gastrocnemius muscles of healthy control and C26 bearing mice (n=5 in each 
group). (C) Nox4 mRNA level in C2C12 myotubes upon treatment with cancer cell-
CM with or without adenoviral (Ad) expression of Sirt1.  Data are mean ± S.E.M, 
compared with Student’s t-test (A-B), One-way ANOVA with Bonferroni’s multiple 






































We wanted to illustrate whether a simplistic flow of events could explain the entire 
mechanism. To investigate this pathway further, we utilized, GKT137831 to inhibit 
Nox4 activity248, BMX-001 to scavenge oxygen radicals249 and AS1842856 to 
inhibit FoxO1 activity250 (Figure 30).We observed that MuRF1 (Trim63) and 
Atrogin-1 (Fbxo32) were downregulated by targeting all the arms of the pathway 
(Figure 31). We would like to mention that our proposed mechanism in no way 
























Figure 31 : Expression of atrophy genes upon treatment with inhibitors.  The 
mRNA levels of Trim63, Fbxo32 in C2C12 myotubes treated with control or cancer 
cell-CM with, GKT137831 (10µM), AS1842856 (0.1µM), NBD (5µM), and BMX-
001 (1µM) for 24 hrs. Data are mean ± S.E.M., One-way ANOVA with Bonferroni’s 
multiple comparisons, treated samples are compared to the non-treated samples. 




Nox4 expression in skeletal muscles drives cancer-induced cachexia 
We next wanted to investigate whether Nox4 expression in muscles contributes to 
cancer cachexia. For this purpose, we generated mice with tamoxifen-inducible 
conditional knockout of Nox4 in the skeletal muscles (Nox4fl/fl; ACTA1-Cre/Esr1; 
Figure 32A). We confirmed the muscle-specific Nox4 knockout after tamoxifen 


































Figure 32 : Nox4 overexpression drives cachexia in orthotopic pancreatic 
tumor models. (A) Schematic illustration of pancreatic cancer-cachexia model 
utilizing Nox4fl/fl; ACTA1-cre/Esr1 mice. (B) Immunoblot analysis of muscle 
extracts from control and Nox4 knockout mice depicting deletion of Nox4 in the 




















Next, we orthotopically implanted mouse pancreatic cancer cell line (KPC 1245) 
into the pancreas of Nox4fl/fl; ACTA1-Cre/Esr1 mice.  We then randomly divided 
the mice into two groups- to be injected with Tamoxifen (Nox4-KO) or solvent 
control (Nox4-WT). Nox4 knockout in muscles significantly rescued tumor-induced 
body weight loss, compared to the Nox4-WT mice (Figure 33A). Additionally, we 
also observed that Nox4 knockout significantly rescued the tumor-induced loss in 
forelimb grip strength (Figure 33B) and gastrocnemius muscle weight (Figure 


























Figure 33 : Nox4 Knockout in muscles rescues atrophy in tumor-bearing 
mice. (A) Change in body weight of mice after 21 days of implantation. (B) Grip 
strength of tumor-bearing Nox4 WT and Nox4 knockout mice on the 18th day post 
implantation. (C) Post necropsy gastrocnemius muscle weight of healthy control 
(n=10), tumor-bearing Nox4 WT (n=8) and tumor-bearing Nox4 knockout (n=8) 
mice.  Data are mean ± S.E.M., One-way ANOVA with Bonferroni’s multiple 









It is important to mention here that there was no significant difference in tumor 
weights between the two groups (Figure 34A), implying that the changes in muscle, 
body weight and muscle function were predominantly due to changes in muscle 
physiology. Additionally, gastrocnemius muscle tissue sections stained with 
hematoxylin and eosin stain demonstrated a decrease in the muscle fiber cross-
sectional area in the tumor-bearing mice, and these effects were rescued by 
























Figure 34 : Nox4 knock out regulates muscle atrophy in tumor-bearing mice.  
(A) Post-necropsy tumor weights from tumor-implanted Nox4 WT and Nox4 KO 
mice. (B) Representative hematoxylin and eosin-stained muscle sections depicting 
changes in the muscle fiber cross-sectional area. Scale bars represent 25µm.  
Quantification of the gastrocnemius muscle cross-sectional area of healthy 
controls and tumor-implanted mice (n=3). Data are mean ± S.E.M., One-way 












Next, we also evaluated the molecular markers in the muscles of the tumor-bearing 
mice. We also observed that Nox4 knockout was able to rescue the decreased 
myosin heavy chain levels in the tumor-bearing mice. Consequently, the tumor-
induced increase in MuRF1 and ATROGIN-1 levels in the mice muscles was also 
abolished by Nox4 knockout (Figure 35A). Interestingly, Nox4 knockout did not 
have an impact on SIRT1 stabilization, implying the importance of targeting Nox4 
independent of SIRT1 (Figure 35A). This might also imply Nox4 acting downstream 
of Sirt1. Nox4 knockout also abrogated the tumor-induced mRNA levels of FoxO 
transcription factors (Figure 35B). Therefore, these studies suggest that targeting 























Figure 35 : Nox4 regulates atrophy and FoxO genes in cachectic muscles.  
(A) Immunoblot analysis of muscle extracts from healthy control, Nox4 WT and 
Nox4 KO tumor-bearing mice. (B) Foxo1 and Foxo3 mRNA levels in 
gastrocnemius muscles from control and tumor-implanted mice (n=5 for each 
group). Data are mean ± S.E.M., One-way ANOVA with Bonferroni’s multiple 

















Pharmacological inhibition of Nox4 rescues cancer cachexia in mice models 
 
For clinical relevance of this study, we wanted to target Nox4 pharmacologically. 
We next investigated the potential of GKT137831 (henceforth referred to as GKT), 
a NOX4/NOX1 inhibitor to rescue cachexia in pancreatic cancer mouse models. 
This compound was our best option since it has already passed the Phase I safety 
trial and is currently in Phase II for diabetes (NCT02010242) and primary biliary 
cholangitis (NCT03226067). To evaluate the efficacy of GKT on cancer cachexia, 
we implanted human pancreatic cell line S2-013 in 20 athymic nude mice and 
randomly segregated them into two groups of 10 mice each. We started daily 
treatment with GKT or vehicle control via oral gavage after 6 days post-
implantation (Figure 36A). Three weeks after implantation, mice were sacrificed 
and analyzed. We observed body weight loss in S2-013 tumor-bearing mice that 
was rescued by treatment with GKT (Figure 36B). There was no difference in tumor 
weight upon treatment with GKT, implying that these effects were muscle-specific 



























Figure 36 : Pharmacological inhibition of Nox4 rescues muscle wasting in a 
cancer cachexia model. (A) Schematic illustration of S2-013 tumor cell 
implantation and GKT therapy initiation in athymic nude mice. (B) Change in the 
mouse body weight at day 21 post implantation for healthy controls (n=9), healthy 
controls with GKT (n=4), S2-013-implanted (n=9), and S2-013-implanted with GKT 
treatment (n=10). (C) Post-necropsy tumor weight for S2-013-implanted mice with 
and without GKT treatments. Data are mean ± S.E.M. One-way ANOVA with 





We observed that GKT could rescue tumor-mediated decrease in gastrocnemius 
muscle weight, body fat content, and grip strength (Figure 37A-C). We also 
observed an increase in the reactive oxygen free radicals in the gastrocnemius 
muscles of tumor-bearing mice by performing EPR spectroscopy; the increase was 







































Figure 37 : GKT rescues muscle wasting in tumor-bearing mice. (A) 
Gastrocnemius muscles for S2-013-implanted mice with and without GKT 
treatments. (B) Body fat percent at day 18 in tumor-bearing mice with and without 
GKT treatments. (C) Grip strength measurements on day 18 post implantation. (D). 
Gastrocnemius muscle ROS measurement by EPR in tumor-bearing mice with and 
without GKT treatment (n=5 for each group). Data are mean ± S.E.M., One-way 

























































































































GKT treatment also abrogated the tumor-induced decrease in gastrocnemius 
muscle fiber cross-section area, as observed by performing tissue staining with 
hematoxylin and eosin (Figure 38A). Analysis of molecular markers of atrophy by 
immunoblotting demonstrated GKT-mediated rescue in the levels of myosin heavy 
chain, ATROGIN-1 and MURF1 (Figure 38B). Moreover, SIRT1 levels were not 
stabilized up to control levels upon GKT treatment, implying again that SIRT1 is 
an upstream regulator of Nox4 (Figure 38B). GKT treatment also diminished the 
tumor-induced mRNA expression of FoxO transcription factors (Figure 38C). 
Therefore, we concluded that pharmacological inhibition of NOX4 in the PDAC 


























Figure 38 : GKT rescues muscle atrophy via FoxO pathway.  (A)  
Representative images of hematoxylin and eosin-stained gastrocnemius muscle 
cross-sections. Quantification of the cross-sectional area measured via ImageJ 
(n=3). Scale bars represent 100µm. (B) Immunoblot analysis of gastrocnemius 
muscle extracts from mice with indicted treatments. (C) FoxO1 and FoxO3 mRNA 
levels in gastrocnemius muscles from mice with indicted treatments (n=3 for each 
group). Data are mean ± S.E.M., One-way ANOVA with Bonferroni’s multiple 







To validate whether this phenotype was clinically significant, we performed Nox4 
staining on skeletal muscle tissue sections from human pancreatic cancer patients 
obtained from the Rapid Autopsy Program and observed a significant negative 
correlation between the muscle fiber cross-section area and staining intensity 
(Figure 39A and 39B).  This demonstrated that cachectic patients have an 
increased expression of Nox4 in their muscles. 
We concluded our study by establishing the pathway illustrated in Figure 40 and 




























Figure 39 : Nox4 expression in human PDAC muscle samples. (A) 
Representative images of NOX4-stained human muscle specimens. (B) 
Correlation of Nox4 staining histoscore and muscle fiber cross-sectional area in 






Figure 40 : Schematic illustration of the action of resveratrol and GKT as 















Since SIRT1 is a known regulator of oxidative stress244, we screened for the 
redox regulators that were induced by cancer cell-CM. Our screening identified 
Nox4 to be the key oxidative stress regulator that was upregulated in the muscles 
of tumor-bearing mice, an effect that was abrogated by resveratrol treatment. 
Notably, Nox4 is also demonstrated to be upregulated in angiotensin II-induced 
muscle wasting, implying the possibility of a common pathway261 in multiple muscle 
disorders. Moreover, NOX4 expression also demonstrated to have a significant 
negative correlation with the skeletal muscle fiber cross-sectional area in human 
pancreatic cancer patients. Previous studies have demonstrated that Nox4 is 
regulated by NF-κB in different models245,246. Herein, we demonstrate that Nox4 
promoter occupancy by NF-κB and NF-κB activity are significantly induced by 
tumor cell-CM, and the effect is abrogated by resveratrol. Furthermore, muscle-
specific Nox4 knockout and pharmacological blockade of Nox4 in tumor-bearing 
mice abolished tumor-induced muscle atrophy. We also observed a decrease in 
the expression of Nox4-induced FoxO expression. These studies demonstrate that 
SIRT1 regulates oxidative stress and atrophy in skeletal muscles by NF-κB-
mediated expression of FoxO. Interestingly, GKT137831, a Nox1/Nox4 inhibitor, 
which is in clinical trials for various diseases, can potentially be utilized in a muscle 
wasting syndrome.  
Overall, this study demonstrates that tumor-induced muscle wasting was 
mediated by the SIRT1 loss-triggered activation of NF-κB, which in turn induces 
the expression of Nox4 in skeletal muscles, leading to induction of the protein 
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degradation pathways. These findings provide new insights into the mechanisms 
that underlie weight and muscle loss in cancer cachexia. These studies also 





Chapter 5: Role of Oxidative Stress in Chemotherapy-
Induced Muscle Atrophy in Pancreatic Cancer 
 
(Note- The data in this chapter is under preparation to be submitted to a peer-reviewed 




Cancer-associated cachexia limits cancer therapy, quality of life and survival209,210. 
In 2011, the international consensus defined cancer cachexia as a multifactorial 
syndrome with ongoing loss of skeletal muscle mass, with or without loss of fat 
mass. This weight loss cannot be fully reversed by conventional nutritional support 
and leads to progressive functional impairment3. To update the definition of 
cachexia, Vagnildhaug et al. have recently established a weight loss grading 
system (WLGS) which is related to survival and progression of the disease in 
cancer patients262. This grading system considered the body mass index (BMI) and 
the degree of weight loss of the patient and is now included in the international 
practice guidelines of the European Society for Clinical Nutrition and Metabolism 
(ESPEN). However, even though BMI has been demonstrated to play a role in 
determining the prognosis of the patient, studies have also established skeletal 
muscle mass loss as a negative prognostic factor, regardless of overall body 
weight263.  Onesti et al. (2016) have found sarcopenia to be a predictor of overall 
survival (OS) in male patients undergoing pancreatic resection264. Similarly, a 
study conducted in Japan by Ninomiya et al. (2017) showed sarcopenia to be a 
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valid prognostic factor as tumor size and resection margins in patients undergoing 
surgical resection for pancreatic ductal adenocarcinoma7. 
Additionally, studies have also demonstrated that chemotherapy alone can 
induce muscle wasting in experimental mice models265. In 2016, Baretto et al. also 
reported that cancer and chemotherapy contribute to weight loss by activating the 
same pathways in colon tumor-bearing mice models. These pathways included 
mitochondrial dysfunction, alteration in the TCA cycle, fatty acid metabolism and 
modification of reactive oxygen species, to name a few176. These studies have 
shed light on the importance of elucidating the mechanism of chemotherapy-
induced muscle wasting. 
The goal of our study was to determine the correlation between skeletal 
muscle depletion and survival outcomes in patients with pancreatic cancer. Since 
our patient cohort was either treated with gemcitabine or FOLFIRINOX, we wanted 
to evaluate the effect of these chemotherapeutic agents on body weight loss and 
muscle wasting in an experimental murine model. Moreover, we also wanted to 
elucidate the pathway which leads to muscle wasting and attempt to combat the 
wasting via pharmacological intervention.  
Since chemotherapy has been demonstrated to increase ROS in cancer 
cells266 in its process to abolish it, we hypothesized that chemotherapy would be 
increasing ROS in other tissues, including skeletal muscles. In this chapter, we will 
illustrate our findings on the and the role of oxidative stress in chemotherapy-




Muscle-loss correlates negatively with survival in pancreatic cancer 
patients after therapy 
We collected the clinical data for the patients at two separate time points: at 
diagnosis and at eight weeks after the start of therapy. At the same timepoints 
calculation of the muscle mass value was performed for each patient using the 
Slice-O-Matic software (Figure 41A). We subdivided the patients into three groups 
based on the degree of muscle loss at 8 weeks compared to the time of diagnosis. 
Majority of the patients (57%) had less than 10% muscle loss or had muscle gain, 
twenty-nine percent had 10-20% muscle loss, and the remaining fourteen percent 
had muscle loss that was greater than 20%. Kaplan-Meier curves demonstrate that 
patients with continuous muscle loss during the first eight weeks of therapy have 
inferior PFS (p-value = 0.027), Figure 1, and OS (the p-value = 0.038). Adjusting 
for a list of confounders, the p-value is 0.038, indicating a significant risk of death 



















Figure 41 : Muscle loss in Pancreatic Cancer Patients leads to poor 
prognosis. (A) Representative images of abdominal muscles around the L3 
lumbar vertebrae before and after 8 weeks of chemotherapy. (B-C) Overall and 
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Table 3 : Patient characteristics for L3 muscle measurement. 
  
Demographic Frequency (N=162) Frequency percent (%) 









Stage I-II  
           III  







Rx      Gemcitabine 
           FOLFIRINOX 
           Others 









Resection   Yes 
                 
56 34.57 
Muscle loss <10%  





BMI                <10% 







Effect of Chemotherapy on Muscle Mass and Function in Mice 
 
To generate an experimental model to study the effect of chemotherapy on 
muscles, we treated normal mice with Gemcitabine or FOLFIRINOX for a period 
of 8 weeks (Figure 42A). The doses of gemcitabine and FOLFIRINOX were similar 
to those used in experimental cancer models201,267. We observed a decrease in 
body weight, grip strength and rotarod performance upon treatment with 




































Figure 42 : Chemotherapy induces loss in body weight and muscle function 
in mice. (A) Schematic illustration of treatment of C57/BL6 with gemcitabine 
(n=12) and FOLFIRINOX (n=12). (B) Measurement of change in body weight after 
8 weeks of chemotherapy treatment; control (n=6), gemcitabine (n=12), 
FOLFIRINOX (n=12). (C) Change in Grip Strength of control, gemcitabine-, 
FOLFIRINOX- treated mice. (D) Change in Rotarod Performance of control, 
gemcitabine-, FOLFIRINOX-treated mice. Data are mean ± S.E.M. One-way 
ANOVA was performed and Tukey’s post-hoc analysis was performed to compare 
all the groups. p<0.001 is indicated as *** to compare gemcitabine and 








Post-necropsy measurements of gastrocnemius muscles depicted a decrease in 
muscle weight (Figure 43A). As mentioned in chapters 3 and 4, muscle wasting is 
characterized by the increase in muscle specific ubiquitin ligases, MuRF1 and 
Atrogin-1, which are responsible for the protein turn over in muscles215,216. 
Therefore, we also measured the mRNA levels of these two genes in the muscles 
of the mice treated with chemotherapy. We observed an increase in the ubiquitin 






























Figure 43 : Chemotherapy induces muscle atrophy in mice. (A) Post-necropsy 
measurement of gastrocnemius muscle of control (n=6), gemcitabine- (n=12), 
FOLFIRINOX (n=12)- treated mice. (B-C) mRNA expression of Trim63 (MuRF1) 
and Fbxo32 (Atrogin-1) in gastrocnemius muscles of control (n=3), gemcitabine- 
(n=3), FOLFIRINOX- (n=3) treated mice. Data are mean ± S.E.M. One-way 
ANOVA was performed and Tukey’s post-hoc analysis was performed to compare 
all the groups (A), Student’s t-test (B-C) was performed. p<0.05 is indicated as *, 







As previously mentioned, studies have demonstrated modification in ROS 
pathways upon treatment with chemotherapy such as FOLFIRI176. We wanted to 
evaluate whether similar pathways were also activated upon treatment with 
gemcitabine and FOLFIRINOX. To this end, we measured the levels of reactive 
oxygen species in the gastrocnemius muscles via Electron Paramagnetic 
Resonance (EPR) by utilizing a superoxide-sensitive probe as demonstrated in 
previous studies268. We observed a significant increase in ROS in the muscles of 























Figure 44 : Chemotherapy induces ROS in gastrocnemius muscles in mice. 
EPR measurement of gastrocnemius muscle of control (n=5), gemcitabine- (n =5), 
FOLFIRINOX (n =5)-treated mice. Data are mean ± S.E.M. Student’s t-test was 



















Pharmacological blockade of oxidative stress rescues chemotherapy-
induced muscle wasting 
 
To combat the increased levels of ROS in the muscles of the chemotherapy-
treated mice, we utilized a superoxide dismutase mimetic, BMX-001 (hereafter 
termed as BMX). This drug acts as a mimic of SOD and is present in the nucleus, 
mitochondria, cytoplasm and the extracellular matrix269. This compound has been 
approved by the FDA270 and is now currently in clinical trials for high grade glioma 
(NCT02655601), head and neck cancer (NCT03386500), multiple brain 
metastasis (NCT03608020) primarily as a radio-protectant. After two weeks of 
treatment with chemotherapy, mice were divided into two groups, and one group 
(n=5) was given BMX and the other vehicle control (n=5) (Figure 45A).  We 
observed that the decrease in body weight, grip strength and rotarod performance 



























Figure 45 : Pharmacological blockade of ROS rescues chemotherapy-
induced body weight loss and muscle function. Schematic illustration of 
treatment of C57/BL6 with Gemcitabine (n=10) and FOLFIRINOX (n=10). After two 
rounds of chemotherapy, 5 mice in each group were treated with BMX-001. (B) 
Measurement of change in body weight after 8 weeks of chemotherapy treatment; 
control (n=10), gemcitabine- (n=5), gemcitabine and BMX- (n=5), FOLFIRINOX- 
(n=5), FOLFIRINOX and BMX- (n=5) treated mice. Data are mean ± S.E.M. One-
way ANOVA was performed and Tukey’s post-hoc analysis was performed to 




















Figure 46 : BMX rescues chemotherapy-induced muscle wasting. (A) Change 
in Rotarod Performance of control, gemcitabine-, gemcitabine and BMX-treated 
mice (B) Change in Grip Strength of control, gemcitabine-, gemcitabine and BMX-
treated mice. (C) Change in Rotarod Performance of control, FOLFIRINOX-, 
FOLFIRINOX and BMX-treated mice. (D) Change in Grip Strength of control, 
FOLFIRINOX-, FOLFIRINOX and BMX-treated mice. Data are mean ± S.E.M One-
way ANOVA was performed and Tukey’s post-hoc analysis was performed to 








We observed a rescue in gastrocnemius muscle weight upon treatment with BMX 
and chemotherapy (Figure 47A). Hemotoxylin and Eosin (H&E) staining of 
gastrocnemius muscle sections demonstrated decrease in cross sectional area 









































Figure 47 : BMX rescues chemotherapy-induced muscle atrophy. (A) Post-
necropsy measurement of gastrocnemius muscle of control (n=10), FOLFIRINOX-  
(n=5), FOLFIRINOX and BMX treated (n=5)- treated mice. (B) Representative 
images of H&E staining of gastrocnemius muscle sections of control (n=3), 
FOLFIRINOX-(n=3), FOLFIRINOX and BMX- (n=3), gemcitabine- (n=3), 
gemcitabine and BMX- (n=3) treated mice. Quantification of gastrocnemius muscle 
cross sections. Data are mean ± S.E. One-way ANOVA was performed and 
Tukey’s post-hoc analysis was performed to compare all the groups. p<0.05 is 







The increase in MuRF1 and Atrogin-1 was abrogated with the use of BMX along 
with chemotherapy (Figure 48A). Moreover, the EPR studies also demonstrated a 
decrease in ROS in the muscles of the mice treated with BMX-001 along with 
chemotherapy (Figure 48B). Therefore, we concluded that chemotherapy-induced 
































Figure 48 : BMX decreases chemotherapy-induced ROS in gastrocnemius 
muscles. (A) mRNA expression of Trim63 (MuRF1) and FBXO3 (Atrogin-1) in 
gastrocnemius muscles of control (n=3), FOLFIRINOX-(n=3), FOLFIRINOX and 
BMX- (n=3), gemcitabine- (n=3), gemcitabine and BMX- (n=3) treated mice. (B) 
EPR measurement of gastrocnemius muscle of control (n=5), gemcitabine- (n =5), 
gemcitabine and BMX, FOLFIRINOX (n =3)-, FOLFIRINOX and BMX- (n=5). 
treated mice. Data are mean ± S.E.M. One-way ANOVA was performed and 
Tukey’s post-hoc analysis was performed to compare all the groups. p<0.05 is 






Pharmacological Blockade of oxidative stress in tumor-bearing mice 
rescues chemotherapy-induced muscle wasting 
In order to have translational relevance, we wanted to investigate whether BMX 
would be successful in rescuing chemotherapy-induced wasting in tumor-bearing 
mice. We orthotopically implanted 40 C57 mice with KPC 1245 cells. We then 
randomly divided them into four groups of 10 mice. We injected one group with 
FOLFIRINOX, second with BMX and the third with FOLFIRINOX and BMX. We 
compared all these groups to the untreated tumor-bearing group. We started the 
BMX treatment at the same time as FOLFIRINOX, after 4 days of tumor-
implantation. Unfortunately, this study did not show us the expected results and 
there was no rescue in body weight or muscle loss with BMX in the tumor-bearing 
mice treated with FOLFIRINOX (data not shown). We re-evaluated our treatment 
strategy and designed another one according to the ongoing clinical trials. We 
pretreated the mice twice with double dose (1mg/kg) of BMX, 4 days and 2 days 
before the start of the chemotherapy. FOLFIRINOX injections started from 4 days 
post implantation. 21 days-post implantation, we observed a significant rescue with 
BMX in body weight of the tumor-bearing mice which were treated with 
FOLFIRINOX (Figure 49). We also observed that FOLFIRINOX treatment of 
tumor-bearing mice caused more weight loss than just tumor-bearing mice, 



















Figure 49: BMX rescues chemotherapy-induced wasting in tumor-bearing 
mice. Change in body weight of healthy control (n=8), KPC tumor-bearing (n=10), 
KPC tumor-bearing treated with FOLFIRINOX (n=10), KPC tumor-bearing treated 
with BMX (n=10), KPC tumor-bearing treated with FOLFIRINOX and BMX (n=10). 
Data are mean ± S.E.M One-way ANOVA was performed and Bonferroni’s post-
hoc analysis was performed to compare all the groups. p<0.05 is indicated as *, 















On the 18th day-post implantation, we recorded the grip strength and latency to fall 
of the mice. We observed that FOLFIRINOX treatment of the tumor-bearing mice 
did not decrease the grip strength of the mice significantly as that compared to 
untreated tumor-bearing mice. However, the decrease in grip strength was 
rescued by BMX (Figure 50A). On the other hand, latency to fall showed a trend 
to decrease in tumor-bearing mice treated with FOLFIRINOX as compared to the 

















Figure 50 : BMX rescues muscle function in chemotherapy-induced cachexia 
in tumor-bearing mice. Decrease in grip strength (A), rotarod performance (B) of 
healthy control (n=8), KPC tumor-bearing (n=10), KPC tumor-bearing treated with 
FOLFIRINOX (n=10), KPC tumor-bearing treated with BMX (n=10), KPC tumor-
bearing treated with FOLFIRINOX and BMX (n=10).  Data are mean ± S.E.M One-
way ANOVA was performed and Bonferroni’s post-hoc analysis was performed to 















Post-necropsy measurements demonstrated decrease in muscle weight of tumor-
bearing mice treated with FOLFIRNOX compared to the untreated group. This 
decrease in muscle weight was rescued by BMX treatment (Figure 51A). It is 
worthwhile to mention that the tumor burden was significantly decreased in the 
group treated with FOLFIRINOX and BMX (Figure 51B). Therefore, we cannot 
conclude that the effect of BMX is strictly due to its effect on the muscles. However, 
due to the lack of better models to study the effect of a compound on skeletal 
muscle wasting independent of it effect on the tumor, we have to depend on the 
results of this study. We were successful in addressing this in chapter 3 but in this 
case, this is the best model available. We believe since BMX is not aggravating 
the tumor, but in turn is working synergistically to shrink it, this compound might be 















Figure 51 : BMX rescues chemotherapy-induced wasting in tumor-bearing 
mice. Decrease in muscle weight (A) and tumor weight (B) of healthy control (n=5), 
KPC tumor-bearing (n=5), KPC tumor-bearing treated with FOLFIRINOX (n=5), 
KPC tumor-bearing treated with BMX (n=5), KPC tumor-bearing treated with 
FOLFIRINOX and BMX (n=5). Data are mean ± S.E.M. One-way ANOVA was 
performed and Bonferroni’s post-hoc analysis was performed to compare all the 












Upon evaluating the molecular markers, we observed an increase in the atrophy 
genes (MuRF1 and Atrogin) in the muscles of the tumor-bearing mice and those 
treated with FOLFIRINOX (Figure 52A and 52B). This increase in atrophy genes 
was rescued upon treating with BMX. We also evaluated the reactive oxygen 
species in the muscles of the mice via EPR and observed an increase in ROS in 
the muscles of the tumor-bearing mice with FOLFIRINOX and a reduction in ROS 
























Figure 52 : BMX rescues chemotherapy-induced ROS in the muscles of 
tumor-bearing mice. mRNA levels of Trim63 (A), Fbxo32 (B) and EPR 
measurements (C) in the muscles of healthy control (n=5), KPC tumor-bearing 
(n=5), KPC tumor-bearing treated with FOLFIRINOX (n=5), KPC tumor-bearing 
treated with BMX (n=5), KPC tumor-bearing treated with FOLFIRINOX and BMX 
(n=5).  Data are mean ± S.E. One-way ANOVA was performed and Bonferroni’s 
post-hoc analysis was performed to compare all the groups. p<0.05 is indicated as 










FOLFIRINOX and gemcitabine are two first line therapies for pancreatic cancer 
patients, which have significantly improved survival of patients271,272. However, 
studies have established that chemotherapy can induce muscle and body weight 
loss in patients.  
We measured the L3 muscle mass in pancreatic cancer patients at 
diagnosis and after treatment and correlated this mass with overall and 
progression free survival. We demonstrated that decreased muscle mass is highly 
prevalent among patients with pancreatic cancer and outperforms BMI as a 
prognostic indicator. Given the retrospective nature of our study, causal 
relationships cannot be determined definitively, and unmeasured confounding is 
possible. However, we tried to minimize this with our use of a well-characterized 
data set and correcting for all known potentially significant confounders. Next, 
selection bias may affect the results, as patients who did not have available CT 
imaging at diagnosis and at the time of next restaging were excluded from analysis. 
Lastly, while we use a data-driven approach to define cachexia at a single time 
point based on survival outcomes, this approach has been widely used in many 
studies with remarkably similar cut points for cachexia across various populations. 
To the best of our knowledge, this is the largest study evaluating the prognostic 
role of muscle wasting in pancreatic cancer patients with significant results.  
Furthermore, our group wanted to evaluate the effect of chemotherapy 
alone on muscle and body weight. Experimental mouse models helped us to 
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demonstrate that FOLFIRINOX and gemcitabine induced body weight and muscle 
weight loss via increasing oxidative stress in the muscles. We validated this finding 
by inhibiting oxidative stress by utilizing a superoxide dismutase mimetic, BMX-
001. This compound was preferred as it is already in clinical trials as a radio-
protector in cancer treatment. It is important to mention that though using an 
antioxidant was sufficient to prevent chemotherapy-induced wasting in mice 
muscles, studies have shown antioxidants to increase tumor growth in 
experimental models273,274. Therefore, this observation validated our use of BMX-
001, which has been demonstrated to be a pro-oxidant in tumors while being 
antioxidants in other tissues275-277. However, we observed that FOLFIRINOX did 
not increase the ROS levels in the muscles above the level of just the tumor-
bearing mice. We, therefore hypothesized that there might be an increased 
oxidative damage which was not measured in the snapshot of the EPR 
measurement. This might be because EPR only measures free oxygen radicals 
present in the tissues and not damage that has already taken place. For this 
purpose, we are currently evaluating oxidative damage in the muscle tissues. We 
observed that BMX was able to rescue FOLFIRINOX induced wasting in 
pancreatic cancer models. Future studies are needed to demonstrate the effect of 
similar compounds in cancer models, but we believe our study is the first to provide 





Chapter 6: Discussion and Perspectives 
 
Cachexia has been identified as a syndrome for centuries. Hippocrates had 
eloquently described this syndrome, “The flesh is consumed and becomes 
water…the shoulders, clavicles, chest and thighs melt away…the patient becomes 
thin and dry…this illness is fatal.. [Regardless of cause] the treatment is similar; 
but few survive…” Even though there has been evidence of this syndrome in the 
medical literature for centuries, it has been shunned by the scientific community 
as a symptom of the disease and not a disease itself. This idea has changed 
immensely in the last couple of years wherein groups have demonstrated an 
increase in survival rates in preclinical models just by preventing cachexia and not 
decreasing the tumor burden. Our study adds to the increasing knowledge and 
understanding of this field and establishes unexplored avenues, to make a 
difference in combating this syndrome. 
Our study revolved mainly around pancreatic cancer, since it is 
characterized by a dismal rate of survival and poor quality of life. Even after 
therapy, the five-year survival rate is one of the least amongst all cancers. The low 
survival rate is attributed to late diagnosis and early metastasis. Moreover, this 
dismal survival can also, in part, be attributed to cachexia since about 80% of 
pancreatic cancer patients suffer from this syndrome208. The diagnosis of muscle 
wasting is a part of the manifestation of pancreatic cancer and studies have 
attributed inflammatory cytokines released by the tumor and the host body to be 
the main culprit behind muscle wasting. Based on this hypothesis, clinical trials 
have been performed targeting inflammatory cytokine but without any significant 
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success. This has led to a lot of curiosity and urgency in finding newer targets and 
therapeutic interventions and each study tells us a little more about this devastating 
syndrome. 
Chapters 3 and 4 of this dissertation deal with investigating novel targets 
other than the inflammatory pathways, which are involved in the induction of 
cachexia. We focused on sirtuins because they are the switches between signaling 
pathways and metabolic networks and have been shown to play a role under 
energy modulations in the cell.  Consequently, we did find a sirtuin, Sirt1, to be 
altered in all our cachectic models. Upon further analysis, we found that one of its 
downstream targets was NF-κB. This was again intriguing, since NF-κB is also 
regulated via cytokines. But clinical trials using anti-inflammatory agents did not 
show any success. This raises many questions - do other signaling pathways work 
through the same axis as cytokines but have different downstream mechanistic 
regulators? In that case, would it be necessary to target both arms of the pathway? 
We would also like to mention here that we did not observe a consistent difference 
in cytokine profiles in our models of cachexia as compared to the pancreatic 
epithelial cells or non-cachectic pancreatic cancer (data not shown). This 
observation also led us to speculate the validity of exploring inflammatory 
pathways as a therapeutic intervention for cancer cachexia. 
We followed the axis downstream from NF-κB hypothesizing the role of 
ROS in induction of muscle atrophy. Subsequently, we found Nox4 to be 
modulated in cachectic muscles. Nox4 is also found to be upregulated in other 
disorders such as muscular dystrophy and hypertension. This led us to another 
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question – if the presence of a tumor is not necessary for the induction of this 
protein in the muscles, then can this phenotype be attributed to tumor-secreted 
factors or if is this a common defense mechanism of the body against any kind of 
disorder, inflammation or injury? Cachexia or muscle wasting is not only seen in 
cancer but also in diseases such as heart failure, chronic obstructive pulmonary 
disorder (COPD) and tuberculosis. All of these diseases lack an uncontrolled 
growing mass of cells. Therefore, the question is what is the systemic assault 
which is common amongst all these disorders that leads to the same phenotypic 
appearance and sometimes, also the same markers such as upregulation of 
Nox4? We hypothesize that the liver and the hypothalamus may be playing a role 
in this process. As previously mentioned in the Introduction of this dissertation, 
hepatic metabolism is closely linked to skeletal muscle metabolism and this might 
be common factor in all the diseases. There are liver-associated CD68+ 
macrophages which might be playing a role as well. Another important player in 
wasting is the hypothalamus, which has receptors for adipokines and is prone to 
inflammation via cytokines278. It is possible that an inflamed hypothalamus elicits 
its effects in a similar way in all these diseases. However, due to time constraints 
we did not attempt to answer these questions.  
The fifth chapter of this dissertation investigates the effect of chemotherapy 
on body and muscle weight loss. We found that chemotherapy on its own has a 
negative effect on body and muscle weight loss without the presence of a tumor. 
This result was neither counterintuitive or surprising, since the chemotherapies 
used to treat pancreatic cancer are extremely toxic agents. They are almost 
154 
 
equivalent to being called the necessary evil in the context of cancer treatment. 
These agents are known to increase ROS in the tumor cells in order to destroy 
them, therefore we hypothesized the same pathway of degeneration in the muscle 
cells. We did observe an increase in ROS in the muscles of the mice treated with 
chemotherapy. Consequently, our rationale pointed to the same pathway as 
described in chapter 4. Did we just unravel a common pathway via which both the 
tumor and chemotherapy are inducing muscle atrophy? Yes, we observed Nox4 
to be upregulated in these muscles too (Data not shown). We pursued it and 
treated the mice with FOLFIRINOX and GKT, hoping to rescue the wasting similar 
to the tumor-bearing mice. Unfortunately, GKT was unable to rescue 
chemotherapy-induced cachexia. This might imply that though Nox4 is 
upregulated in the muscles, it might not be one of the main regulators of ROS 
induction. There might also be more confounders, such as compensation from 
other enzymes or drug interactions. Next, we attempted to utilize BMX to rescue 
chemotherapy induced wasting, the successful results of which, are discussed in 
chapter 5. BMX also proved to be able to combat chemotherapy-induced cachexia 
in tumor-bearing mice and might be a potential contender for clinical trials. 
We would also like to mention that our studies focused mainly on skeletal 
muscle wasting in cachexia. Although we did measure fat content via DEXA 
scanning and post-necropsy adipose tissue weight, we did not investigate the 
mechanisms leading to adipose tissue wasting. To assess muscle function, we 
performed grip-strength and rotarod measurements. These are the gold-standard 
measurements for cachexia studies. Post-necropsy, we measured the 
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gastrocnemius muscles of the mice to assess muscle weight change. In future 
studies, we plan to measure more of the muscle groups of the leg – the quadriceps, 
external digitalis and the soleus. We utilized CT scans of patients to measure the 
muscle mass around the L3 vertebrae, which is currently the most accurate 
method of detecting loss of muscle mass.  Similarly, we also plan to measure the 
lean body mass of mice via Magnetic Resonance Imaging (MRI) for a more 
accurate measurement of muscle mass. 
 Moreover, we focused on the mechanisms leading to protein degradation 
in the cachectic muscles. There are also studies which focus on the role of muscle 
stem cells in cancer-cachexia. It has been demonstrated that there is impaired 
regeneration of muscle cells in cachectic muscles. Therefore, in addition to protein 
degradation, the cachectic muscles possess the inability to regenerate the muscle 
fibers. It would be interesting to study the role and expression of Sirt1 and Nox4 in 
the muscle stem cells in the cachectic muscles. We could also determine the status 
of muscle stem cells in our models and treatments and, investigate whether 
oxidative stress plays a role in reprogramming the muscle stem cell fate.  
The use of antioxidants has been controversial in the treatment of cancer 
since it is shown to exacerbate the disease273,279. Therefore, it is not recommended 
that any antioxidant be used to scavenge the ROS generated in the muscles due 
to the tumor or chemotherapy. Interestingly, BMX-001 has been shown to act as 
an antioxidant in normal tissues and as a pro-oxidant in tumor tissues (Data 
generated by collaborators, not shown). We demonstrated that this compound was 
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successful in attenuating the high levels of ROS in cachectic muscles. However, 
we have not examined its effect on the oxidative state of the tumor.  
Furthermore, our laboratory has observed distinct metabolic profiles in 
cachectic and non-cachectic pancreatic cancer patients. We have already 
demonstrated that SIRT1 and Nox4, two genes which can regulate various 
metabolic homeostasis pathways, are differentially expression in cachectic and 
non-cachectic PDAC patients. Studying the metabolomic profiles further can 
reveal the metabolic cues which might be regulating Sirt1 and Nox4. Since, we 
have access to patient samples of various stages, it would also be intriguing to 
map the metabolic and the genomic profile of these patients and analyze the 
pathways and genes, which give rise to this syndrome at various stages of cancer 
progression.  
Our studies with two different models of cancer and chemotherapy-induced 
cachexia point towards a serious concern in cachexia research. The ongoing 
research attempting to combat cachexia in preclinical models do not consider the 
involvement of chemotherapy. Though these studies are important to elucidate the 
pathways and mechanisms involved in the induction of cachexia, their translational 
value cannot be truly assessed unless the effect of chemotherapy is also 
considered. This is because it would be highly unlikely for patients to be treated 
for cachexia and not for tumor burden. 
There is still much to be done in the field of cancer cachexia. We have been 
successful in establishing novel targets, such as SIRT1 and Nox4, in cancer-
induced cachexia. It is also important to mention that our studies in the chapters 3 
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and 4 established that the alterations in Sirt1 and Nox4 were the cause of the 
syndrome and not the result of the tissue damage. This is because overexpressing 
both these proteins rescued or degraded myotubes, respectively. We have also 
illustrated the role of oxidative stress in the induction of chemotherapy-induced 
cachexia which can be reverted with the use of BMX-001. The most promising 
factor of our studies is that all our therapeutic interventions have already passed 
the first phase of clinical trials and have been deemed safe for use. Our ongoing 
studies include investigating the effect of tumor and chemotherapy on cardiac 
muscle and function and, the role of post-translational modifications in cachectic 
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